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The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guano-
sine monophosphate (cGMP) signalling pathway plays a fundamental
role in modulating diverse physiological processes including blood
flow, fibrosis, inflammation, and metabolism. sGC stimulators are
small-molecule, heme-dependent agonists of sGC that synergize with
and enhance endogenous NO signaling. As such, sGC stimulators
may provide therapeutic benefits both in diseases associated with
impaired NO signaling and in diseases where stimulation of this
pathway will restore functional homeostasis. Data from our recent
preclinical studies add to the growing body of evidence that sGC
stimulators have direct effects on systemic and vascular inflamma-
tion, fibrosis, and metabolism. Ironwood is developing IW-1973 and
IW-1701 as oral, once-daily sGC stimulators for both cardiovascular
and non-cardiovascular systemic disease indications. Phase 1 studies
in healthy human subjects demonstrated clear evidence of target en-
gagement, attractive pharmacokinetic properties, and predicted
hemodynamic effects, at well-tolerated doses. Phase 2 studies are
currently ongoing in patients with achalasia, an esophageal motility
disorder, and in patients with diabetes and hypertension. Preclinical
characterization of IW-1973 and IW-1701 support the broad thera-
peutic potential and multi-faceted pharmacology of these com-
pounds. Based on preclinical studies, IW-1973 has extensive
distribution into organs including liver, heart, kidney, and lung, which
may maximize effects on target organs while limiting systemic
hemodynamic effects. The pharmacokinetic profile of IW-1701 has a
narrow peak-to-trough ratio, which may provide more consistent
pharmacological effect throughout the dosing interval. Ironwood is
also developing IW-6463, a novel, CNS-penetrant sGC stimulator that
shows target engagement and effects on regional blood flow in the
brain. Preclinical data suggest that IW-6463 may be useful in treating
CNS disorders including vascular dementia and Alzheimer’s disease.
We believe that sGC stimulation, alone or in combination with other
mechanisms, may afford therapeutic benefit in multiple diseases. Fur-
thermore, there may be an opportunity to provide targeted treat-
ments by selecting compounds that are well-suited for specific
diseases based on pharmacological profile, tissue distribution,
pharmacokinetics, and route of administration.© The Author(s). 2017 Open Access This artic
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The NO/cGMP signaling cascade plays a pivotal role in regulation of
the cardiovascular system. The relaxation of vascular smooth muscle
cells is one key mechanism by which NO-driven cGMP elevation is re-
ducing blood vessel tone. Therefore, stimulators of the soluble gua-
nylate cyclase (sGC stimulators), which significantly stimulate cGMP
production, can cause a dose-dependent relaxation of blood vessels
with impact e.g. on pulmonary hemodynamics. The sGC stimulator
riociguat can e.g. reduce pulmonary artery pressure and is approved
for the treatment of pulmonary hypertension (PAH/CTEPH). In recent
years, it became obvious that the second messenger molecule cGMP
does not only induce smooth muscle cell relaxation but might also
target a variety of other cells and tissues and could also influence
tissue remodeling and fibrosis. Therefore, the application of cGMP-
increasing sGC stimulators and sGC activators might have a substan-
tially broader treatment potential with additional therapeutic
applications also for the treatment of fibrotic diseases.
Given the potential antifibrotic mode of action of sGC stimulators,
we investigated if sGC stimulators could become a potential treat-
ment option for Systemic Sclerosis (SSc). SSc is a connective tissue
disease, characterized by excessive skin fibrosis, but also fibrosis of
internal organs as lungs and kidneys, causing a high morbidity and
increased mortality. There is still a significant unmet medical, espe-
cially for approved antifibrotic treatments since only symptomatic
treatment options and treatment recommendations are currently
available.
The sGC stimulators BAY 41-2272 and BAY 63-2521 (riociguat) were
profiled in vitro and in vivo in preclinical models of SSc and skin fi-
brosis. In vitro, the sGC stimulators reduced collagen production in
human dermal fibroblasts, reduced fibroblast-to-myofibroblast differ-
entiation of human dermal fibroblasts, reduced established myofibro-
blasts and inhibited transforming growth factor beta (TGF-ß)le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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fibrosis, prevented skin fibrosis in the bleomycin model, reduced skin
fibrosis in the genetic tight skin (TSK-1) mouse model, reduced skin
and intestinal fibrosis in the chronic graft versus host disease
(cGvHD) mouse model and promoted wound healing in TSK-1 mice.
These in vivo effects were seen at dosages which do not cause pro-
hibitive blood pressure lowering effects.
In summary, these preclinical results demonstrated in a broad set of
animal models for SSc and skin fibrosis with various etiologies, a
dose-dependent regression of skin fibrosis and improvement of
wound healing. These data therefore, suggested to further explore
the treatment potential of the sGC stimulator riociguat in SSc pa-
tients. Currently a randomized, double-blind, placebo-controlled
phase II study to investigate the efficacy and safety of riociguat in
patients with Systemic Sclerosis (dcSSc), RISE-SSc, is ongoing
(NCT02283762).
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Background:
Therapies which restore cyclic GMP (cGMP) levels within the kidney
are hypothesized to slow disease progression. We evaluated the
effects of BI703704, a soluble guanylate cyclase (sGC) activator,
EX76637, a sGC stimulator, and EX77619, a phosphodiesterase type 5
(PDE5) inhibitor on the progression of diabetic nephropathy in obese
ZSF1 rats.
Methods:
Male ZSF1 rats, implanted with telemetry devices, were treated with
either BI703704 at 2 mg/kg, EX76637 at 1 or 3 mg/kg, or EX77619 at
5 or 15 mg/kg for 10 weeks, during which mean arterial pressure
(MAP) and urinary protein excretion (UPE) were determined. At study
end, glomerular and renal interstitial lesions were assessed. Alpha
smooth muscle actin (α-SMA, a marker of myofibroblast activation)
and p57 (a marker of podocyte health) were determined by immuno-
histochemistry. Renal cGMP levels were quantified as a measure of
target engagement.
Results:
By Week 10, similar reductions in MAP were achieved (~8 mmHg)
across treatment groups vs. vehicle. In parallel, sGC activation re-
sulted in significant reductions in UPE (-31% vs veh), while there was
no significant effect of EX76637 (+4% at 1 mg/kg; -16 % at 3 mg/kg
vs veh), or EX77619 (-15% at 5 mg/kg; -9% at 15 mg/kg vs veh).
Importantly, the effects of BI703704 on UPE were accompanied by
reductions in the incidence of glomerulosclerosis (-21% vs veh), while
neither EX76637 nor EX77619 was effective. In addition, interstitial le-
sions were modestly reduced by BI703704 (-13 % vs veh) and
EX77619 (-18% vs veh). α-SMA was reduced by BI703704 (-27% vs
veh) and EX76637 (-8% vs veh), while p57 was significantly increased
by BI703704 (+11% vs veh) but not by EX76637 or EX77619. Import-
antly, target engagement was confirmed for EX77619.
Conclusions:
Despite similar effects on MAP, BI703704 was superior to EX76637 or
EX77619 in reducing proteinuria and preventing renal damage in kid-
neys of ZSF1 rats.
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Background:
Natriuretic peptides play an important role in the regulation of blood
pressure. Hypertension is associated with an impaired natriuretic
peptide system and a reduced natriuretic peptide receptor-A (NPR-A)
activation. Atrial (ANP) and brain natriuretic peptide (BNP) activate
NPR-A, causing production of cyclic GMP (cGMP). Administration of
recombinant BNP has shown effective blood pressure reduction in
uncontrolled hypertension, suggesting BNP as a potential treatment
of uncontrolled hypertension [1]. However, as a potential antihyper-
tensive drug, small molecular compounds could offer better
pharmaceutical properties, such as oral administration and longer
half-life than peptides. Our aim was therefore to identify small mo-
lecular NPR-A agonists and characterize their pharmacological
properties.
Results and Conclusion:
After performing a high throughput screening of about 30,000
small molecular compounds, we identified one compound that
enhanced the cGMP production in NPR-A expressing cells.
Through hit-to-lead optimization, we identified compounds with
higher potency. All of these compounds were characterized as
positive allosteric modulators. In the presence of a small concen-
tration of BNP, these compounds increased the cGMP production
in a concentration-dependent manner, and were also able to in-
crease the maximum BNP-mediated cGMP production. The
compounds were selective towards NPR-A, with little or no effect
on cGMP production in NPR-B expressing cells. Although further
optimization and characterization of these compounds are
needed, positive allosteric modulators of NPR-A can provide a
novel mechanism of action in the treatment of uncontrolled
hypertension.
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Experimentally used as well approved agents that act via nitric
oxide-sensitive guanylyl cyclase (NO-GC) and cyclic guanosine-3',5'-
monophosphate (cGMP)-degrading phosphodiesterase 5 (PDE5) re-
portedly exhibited protection against cardiac ischemia and reper-
fusion (I/R) injury. As NO-GC/cGMP, PDE5 and their major effector
cGMP-dependent protein kinase type I (cGKI) are ubiquitously
present across different cells types in the heart and circulation,
neither the exact cells nor their precise involvement in the
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 3 of 35cardioprotective mechanisms are clear. We herein assessed
whether beneficial effects of the cGMP pathway in the cardiomyo-
cyte require voltage and Ca2+-activated K+ channels of the BK-type
to oppose the myocardial damage during in vivo I/R injury.
The authors declare no conflict of interest.
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NO-sensitive guanylyl cyclase (NO-GC) is accepted to be the major
receptor for the signaling molecule NO. NO-GC is strongly expressed
in platelets and vascular smooth muscle cells. Accordingly, the func-
tions of NO-GC regarding hemostasis and vascular tone have been
investigated intensively. However, the role of NO/cGMP signaling in
many organs involves NO-GC in cells that have not been in broad
focus. Using cell-specific knockout strains for NO-GC in combination
with fluorescent reporter mice, e.g. tdTomato, we are able to investi-
gate NO-GC function in cells that have received less attention over
the years.
In all organs investigated so far, NO-GC is strongly expressed in peri-
cytes. Pericytes are a heterogeneous group of cells as they express
different markers depending on age, development or pathophysio-
logical condition. Two of the best markers, PDGFRβ and desmin, are
colocalized with NO-GC in murine lung. Pericytes in culture show
αSMA expression after stimulation with TGFβ; accordingly, αSMA, a
marker of fibrosis, is strongly upregulated in situ after bleomycin treat-
ment to induce fibrosis. A potential modulatory role of NO/cGMP sig-
naling is indicated by the fact that absence of NO-GC leads to an
increased collagen and αSMA expression upon fibrosis induction.
In the gastrointestinal tract, NO-GC is expressed in smooth muscle
cells but also in interstitial cells of Cajal (ICC) and so-called fibroblast
like cells (FLC). Whereas the function of NO/cGMP in FLC still awaits
clarification, we can show that NO-GC in ICC serves to guarantee
nitrergic neurotransmission as well as development of spontaneous
contractions.
In addition, we have identified NO-GC in colonic myofibroblasts.
These myofibroblasts differ from those in lung by the fact that they
are thought to constitute the stem cell niche for epithelial prolifera-
tion. Deletion of NO-GC using the SMMHC promotor leads to loss of
the enzyme in SMC but also in colonic myofibroblasts. SMC-GCKO
mice develop severe adenomas between 4-6 months of age. The role
of NO-GC in these cells regarding hyperplastic colon polyps is
currently under investigation.
Competing interest
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BMC Pharmacology and Toxicology 2017, 18(Suppl 1):A7The cGMP-dependent protein kinase G I (PKGI) opposes cardiac
hypertrophy and dysfunction, and PKGI-activating drugs remain
under investigation for the treatment of heart failure. The down-
stream mechanisms through which PKGI promotes cardioprotection
remain incompletely understood, suggesting that identifying PKGI
substrates may reveal novel therapeutic targets in the treatment of
cardiovascular disease. We previously identified the PKGI leucine zip-
per (LZ) binding domain to be a critical regulator of cardiac remodel-
ing in response to cardiac pressure overload, and therefore sought to
explore PKGI LZ binding substrates as novel cardioprotective
molecules.
Here we investigated one candidate PKGIα substrate in the myocar-
dium, Mixed Lineage Kinase 3 (MLK3), an upstream regulator of
stress-responsive JNK signaling. We first observed protein-protein
interaction of endogenous PKGIα and MLK3 in myocardium by co-
immunoprecipitation (n=5). Direct PKGIα-MLK3 interaction was con-
firmed with affinity purified proteins (n=4). In primary cardiomyo-
cytes MLK3 mediated cGMP-stimulated JNK phosphorylation (n=3),
and pharmacological MLK3 kinase inhibition induced cardiomyocyte
hypertrophy (n=4, +27.0%). MLK3 protein expression was detected in hu-
man hearts, increased in myocardium from patients with both nonis-
chemic and hypertrophic cardiomyopathy (MLK3/GAPDH: non-ischemic:
6.26 ADU ± 0.85, n=9, hypertrophic: 6.97 ADU ± 1.42, n=8), and in hearts
of mice subjected to cardiac pressure overload (n=8, +138.0%).
MLK3 knockout mice (MLK3-/-) exhibited baseline cardiac hyper-
trophy with preserved cardiac function and structure. In response to
pressure overload, MLK3-/- mice developed accelerated cardiac dys-
function as measured by invasive hemodynamics (n=5-8, LV ejection
fraction, dP/dT max, dP/dT min, and LV end diastolic pressure) com-
pared to MLK3+/+ littermate controls. Pressure overloaded MLK3-/-
hearts had increased hypertrophic (ANP) and fibrotic (Col1a1) gene
expression changes in the heart (n=3-6) suggesting accelerated car-
diac remodeling. Mechanistically, pressure overloaded MLK3-/- mice
exhibited selective impairments in myocardial JNK activation, with no
change in activation of other MAPK proteins.
Together these data demonstrate MLK3 is a novel PKGIα substrate,
MLK3 inhibits adverse cardiac remodeling in vivo, and suggests regula-
tion of myocardial JNK signaling may underlie the cardioprotective ac-
tions of MLK3. This study further supports the approach of exploring
myocardial PKGI-substrates to identify novel cardioprotective molecules.
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Throughout the 20th century it was widely accepted that a light
microscope relying on conventional optical lenses cannot discern de-
tails that are much finer than about half the wavelength of light
(200-400 nm), due to diffraction. However, in the 1990s, the viability
to overcome the diffraction barrier was realized and microscopy con-
cepts defined, that can resolve fluorescent features down to molecu-
lar dimensions. In this lecture, I will discuss the simple yet powerful
principles that allow neutralizing the limiting role of diffraction1,2.
In a nutshell, feature molecules residing closer than the diffraction
barrier are transferred to different (quantum) states, usually a
bright fluorescent state and a dark state, so that they become dis-
cernible for a brief period of detection. Thus, the resolution-
limiting role of diffraction is overcome, and the interior of trans-
parent samples, such as living cells and tissues, can be imaged at
the nanoscale.
References:
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Obesity is a global pandemic and >1.5 billion adults are overweight
(BMI >25 kg/m2), including 500 million who are obese (BMI >30 kg/m2).
Annual US healthcare costs of obesity exceed $150 billion, and by 2030
will exceed 20% of those costs. Obesity reflects over-nutrition, in which
calories eaten exceed those expended metabolically, in part reflecting
dysregulated satiety responses controlling appetite. Beyond the estab-
lished cardiovascular and metabolic sequelae contributing to this mor-
bidity and mortality, there is an established relationship between body
mass and the risk of cancer, including colorectal cancer. Indeed, obese
patients have ~20-60% greater risk of, and ~2-fold higher death rate
from, colorectal cancer. Although the epidemiology of this relationship
is well-established, the precise molecular mechanisms connecting obes-
ity and colorectal cancer remain to be defined. GUCY2C is the receptor
for the paracrine hormones guanylin in the colorectum and uroguany-
lin in small intestine. An emerging paradigm suggests that guanylin
loss disrupting the GUCY2C paracrine signaling axis, and epithelial cell
homeostasis, is a required step in colorectal cancer initiation. Separ-
ately, secretion of uroguanylin into the circulation by the small intestine
forms a gut-brain endocrine axis controlling hypothalamic GUCY2C
regulating satiety and appetite linked to body mass and metabolic
homeostasis. Here, we reveal that over-nutrition and consumption of
excess calories suppresses guanylin and uroguanylin expression, simul-
taneously disrupting GUCY2C paracrine and endocrine signaling axes
at the nexus of obesity and colorectal cancer. Expression of uroguanylin
and guanylin, but not GUCY2C, is reduced in small and large intestine,
respectively, by diet-induced obesity in mice and humans. Hormone ex-
pression appears to be reversibly suppressed by ingested calories
through endoplasmic reticulum stress. In that context, transgenic re-
placement of guanylin in intestine eliminates tumorigenesis induced by
obesity. Further, transgenic expression of uroguanylin in brain improves
satiety responses dysregulated in obesity. These observations suggest a
novel pathophysiological model in which caloric suppression of guany-
lin and uroguanylin silencing GUCY2C is at the intersection of molecu-
lar mechanisms underlying obesity and its associated risk of colorectal
cancer. Moreover, they reveal a correlative therapeutic paradigm which
leverages the preservation of GUCY2C expression in over-nutrition, in
which hormone supplementation reconstitutes endocrine and para-
crine axes to restore appetite control opposing obesity and intestinal
epithelial cell homeostasis preventing tumorigenesis, respectively.
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BMC Pharmacology and Toxicology 2017, 18(Suppl 1):A10Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide sig-
naling pathway, is formed as a heterodimer by various isoforms of its
α and β subunit. sGC is the physiological receptor for nitric oxide
(NO) and NO-releasing drugs. Its activation induces the synthesis of
the second messenger cGMP. cGMP regulates the activity of various
downstream proteins, leading to vascular relaxation, inhibition of
platelet aggregation, and modified neurotransmission.
Recently, genomic studies - genome-wide association studies (GWAS)
in large samples of unrelated probands and exome-sequencing
studies (WES) in extended families presenting with myocardial in-
farction - revealed the importance of rare and common genetic
variation of sGC and other genes involved in NO-signalling, like
NOS3, encoding the endothelial NO-synthase, and PDE5A, on car-
diovascular risk.
Understanding the full spectrum of phenotypic consequences of
rare and common variants may provide insight into the benefits
and risks of pharmacologic manipulation of nitric oxide
signalling.
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Background:
Platelets are circulating sentinels of vascular integrity and are acti-
vated, inhibited or modulated by multiple hormones, vasoactive sub-
stances or drugs. Endothelium- or drug-derived NO strongly inhibits
platelet activation via activation of the soluble guanylyl cyclase (sGC)
and cGMP elevation, often in synergy with the cAMP- elevating pros-
tacyclin. However, the molecular mechanisms and diversity of cGMP
effects in platelets are poorly understood and sometimes contro-
versial. Recently, we established the quantitative human platelet
proteome1, the Iloprost/prostacyclin/cAMP/PKA affected phospho-
proteome2, the interaction of the ADP and Iloprost/prostacyclin-
affected phosphoproteome3 and the effects of Riociguat on hu-
man platelets4. Here, the aim was to establish and analyze the
phosphoproteome after selective stimulation of the sGC/cGMP
pathway by Riociguat in human platelets.
Methods:
Phosphorylation and functional platelet effects of various NO donors
(Sodium nitroprusside, DEA-NO, Sodium S-Nitrosocysteine) and the
sGC stimulator Riociguat were compared. For the full phosphoproteo-
mic study the effect of Riociguat (10 μM, 5 min) was investigated as
the most robust and cAMP-independent cGMP-effector reagent in
platelets and compared to the phosphoproteome of Iloprost (5 nM, 2
min)measured in parallel as described2, 3.
Results:
In total we quantified 8181 phosphorylation sites from 2249 proteins
across three biological replicates. Riociguat increased (>1.5-fold up)
and decreased (>1.5-fold down) phosphorylation levels in 345 and
94 proteins, respectively. The spectrum of proteins covers many
platelet functions including membrane proteins/receptors, signaling
molecules and granule proteins including 24 protein kinases (e.g.
MYLK, CAMKK1/2, CDK16/17/18, BRAF) with increased and 4 protein
kinases (KALRN, KSR2, PAK2, WNK1) with reduced levels. Comparison
of the Riociguat phosphoproteome with the Iloprost (cAMP/PKA)
phosphoproteome showed that there is a significant overlap of
cGMP and cAMP responses at the level of protein phosphorylation
but there are a number of proteins more strongly up-regulated by
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 5 of 35Riociguat. The top-list of Riociguat affected phosphoproteins in-
clude established PKG substrates (VASP, MYLK, ITPR1, PDE5A,
MRVI1 and others) but also others previously not described as
PKG substrates.
Conclusion:
This is the first description of the human platelet phosphoproteome
affected by selective stimulation of the sGC/cGMP pathway. The
magnitude and diversity of the Riociguat/cGMP phosphoproteome
is extensive and significantly overlaps with the Iloprost/cAMP phos-
phoproteome. However, there are number of novel PKG substrates
and some distinct differences between cAMP and cGMP pathway.
The regulated phosphorylation of multiple protein kinases and sig-
nalling molecules by the cGMP/PKG system indicates a substantial
network.
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Background:
A proportion of pulmonary arterial hypertension (PAH) patients fail
to reach/maintain treatment goals with phosphodiesterase 5 inhibi-
tors (PDE5i). RESPITE investigated whether it is safe, feasible, and
beneficial to replace PDE5i with riociguat in PAH patients with aninadequate response to PDE5i. This analysis explored the relationship
between the nitric oxide (NO) signaling biomarkers including cyclic
guanosine monophosphate (cGMP, a 2nd messenger that mediates
smooth muscle relaxation via protein kinase G) and asymmetric
dimethylarginine (ADMA, an inhibitor of NO synthesis), and response
to riociguat.
Methods
RESPITE (NCT02007629) was a 24-week, open-label, single-arm,
Phase IIIb trial in PAH patients in World Health Organization
(WHO) functional class (FC) III, with 6-minute walking distance
(6MWD) 165–440 m, cardiac index <3.0 L/min/m2, pulmonary vas-
cular resistance >400 dyn·s·cm−5, and mean pulmonary arterial
pressure >30 mmHg, despite PDE5i treatment for ≥90 days. Pa-
tients underwent a 1–3-day PDE5i treatment-free period before re-
ceiving riociguat individually adjusted up to a maximum of 2.5 mg
three times daily. Concomitant endothelin receptor antagonists
(ERAs) were allowed. Exploratory endpoints included change from
baseline to Week 24 in 6MWD, WHO FC, N-terminal prohormone of
brain natriuretic peptide (NT-proBNP), and NO signaling-related
and other biomarkers.
Results:
Sixty-one patients (mean±SD age 54±14 years; 74% female) were
enrolled and 51 (84%) completed the study. Patients were pre-
treated with sildenafil (n=40 [66%]) or tadalafil (n=21 [34%]); 50
(82%) were taking concomitant ERAs at baseline. At Week 24,
6MWD and WHO FC were improved, plasma cGMP had increased, and
NT-proBNP decreased compared with baseline (Table 1). Levels of
cGMP and NT-proBNP correlated with PAH severity at baseline and
Week 24. Sixteen patients (34% [n=47]) achieved the composite end-
point of no clinical worsening, WHO FC I/II, and ≥30 m increase in
6MWD. These patients had lower NT-proBNP and cGMP at baseline
compared with those who did not achieve the composite endpoint.
Serious adverse events occurred in 10 patients (16%), 2 of which (3%)
were study drug-related.
Conclusions:
RESPITE demonstrated that riociguat improved WHO FC and
6MWD as well as decreasing NT-proBNP and increasing plasma
cGMP levels among PAH patients who had an inadequate re-
sponse to PDE5i. No new safety signals were observed. The study
provides preliminary evidence that switching from PDE5i to rioci-
guat may be beneficial in PAH patients who are not at treatment
goal with PDE5i. Further studies are needed to confirm if bio-
marker levels may help identify patients who would benefit from
switching to riociguat.
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24 in RESPITE
Mean (SD)
biomarker
Baseline Week 24
n Value at
baseline
n Change from
baseline
p-value for change
from baseline to
Week 24
cGMP (plasma),
pmol/mL
53 16.25 (11.24) 51 +2.61 (8.00) 0.0240
ADMA (plasma),
μmol/mL
52 0.56 (0.13) 49 –0.02 (0.12) 0.2909
NT-proBNP, pg/mL 60 1190 (1828) 51 –347 (1235) 0.0170a
GDF-15, pg/mL 53 4633 (4525) 51 –669 (2977) 0.1150
ST-2, ng/mL 53 21.08 (15.17) 51 –2.34 (9.80) 0.0947
ap-value is for the relative change from baseline in NT-proBNP
Baseline = the last documented value while still receiving PDE5i
ADMA, asymmetric dimethylarginine; cGMP, cyclic guanosine monophosphate;
GDF-15, growth differentiation factor 15; NT-proBNP, N-terminal prohormone
of brain natriuretic peptide; ST-2, suppression of tumorigenicity 2A13
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Introduction:
Non-alcoholic steatohepatitis (NASH), characterized by liver fibrosis,
inflammation, and steatosis, increases a patient’s risk for developing
cirrhosis. IW-1973, a novel soluble guanylate cyclase stimulator en-
hances signalling through the nitric oxide-sGC-cGMP pathway and
has demonstrated effects on blood flow, inflammation and fibrosis in a
variety of tissues in multiple animal models. The aim of this study was
to assess the effects of IW-1973 in rodent models of NASH and fibrosis.
Methods:
IW-1973 effects on TGFβ induced α-SMA expression were measured
in rat liver stellate cells. The effects of acute and chronic dosing of
IW-1973 on liver cGMP production and pVASP were determined in
normal rats. To test the effects of IW-1973 in NASH and fibrosis, two
murine models were used. In the MCD model, mice were fed a me-
thionine and choline deficient high-fat diet and continually dosed for
9-weeks with IW-1973 at 1 and 3 mg/kg/day. In the STAM model, IW-
1973 was administered therapeutically at 1.5,3 and 10 mg/kg/day.
The Thioacetamide (TAA)-induced liver fibrosis model was used with
rats; IW-1973 was dosed therapeutically at 1,3 and 10 mg/kg. Fibrosis
was analysed using histological and immunohistochemical staining.
Inflammation and fibrosis gene expression profiles were performed
in livers using b-DNA technology.
Results:
IW-1973 (10 μM) increased cGMP production in rat stellate cells
from 12.7 +/- 0.1 to 74.7 +/- 1.1 nM. When IW-1973 was added
to the stellate cells 4-days after TGFβ (2.5 ng/mL for 7 days) it
inhibited the profibrogenic activity by > 75%. Oral dosing withIW-1973 in healthy animals resulted in increased liver cGMP and
pVASP compared to vehicle controls (p<0.01) indicating activation
of the NO-sGC-cGMP pathway. IW-1973 reduced inflammation,
steatosis and fibrosis in the MCD model at plasma levels that
have not produced hemodynamic effects in normal mice. Simi-
larly, in the STAM model, IW-1973 reduced COL1A1 mRNA, hy-
droxyproline and Sirius red markers of fibrosis at the 10 mg/kg
dose (P<0.05). IW-1973 was also effective in reducing liver fibrosis
in the TAA rat model. The antifibrotic effect was observed at all
doses (P<0.05).
Conclusions:
IW-1973 is a novel sGC stimulator and enhancer of NO signaling. In-
creases in cGMP by IW-1973 stimulation in rat stellate cells reversed
TGFβ induction of α-SMA production. IW-1973 stimulated the sGC-
cGMP pathway in rat livers and dose-dependently reduced liver fi-
brosis and NASH in animal models at doses that do not affect blood
pressure.
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Background:
Studies over the last decade have investigated the function of nitric
oxide (NO) in the cochlea. NO activates the NO-sensitive guanylate
cyclase and triggers intracellular signal transduction pathways in-
volving cGMP. For cochlear hair cells, the role of NO-mediated cas-
cades is controversial, with studies predicting a protective or
detrimental potential. We examine here the cochlear function of
mice lacking one of the two NO-sensitive guanylate cyclase
isoforms (NO-GC1 KO or NO-GC2 KO). The deletion of NO-GC1 or
NO-GC2 did not influence electromechanical outer hair cell (OHC)
properties, measured by distortion product otoacoustic emissions
(DPOAEs), neither before nor after noise exposure, nor were click or
noise burst-evoked auditory brainstem responses (ABR) thresholds
different from controls. Yet, inner hair cell (IHC) ribbons and audi-
tory nerve responses were significantly less deteriorated in NO-GC1
KO and NO-GC2 KO mice after noise exposure. Consistent with a se-
lective role of NO-GC in IHCs, NO-GC β1 mRNA is present in isolated
IHCs but not in OHCs. Using transgenic mice expressing the FRET-
based cGMP biosensor cGi500, NO-induced elevation of cGMP was
detected in real-time in IHCs but not in OHCs. Importantly, long-
term treatment with NO-GC stimulants led to a decline of auditory
nerve response without change in OHC function in older but not
younger animals.
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We conclude that cGMP signaling via NO-GC participates in the de-
velopment of dysfunctional connections between auditory nerve fi-
bers and sensory cells (synaptopathy) after noise exposure. Cochlear
synaptopathy is thought to cause perceptual hearing deficits in a sig-
nificant number of patients who have clinically normal hearing
thresholds (hidden hearing loss). NO-GC isoforms may thus be future
pharmacological targets for early treatment of noise trauma and pre-
vention of hidden hearing loss.
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Clinical background:
Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung
disease that results in fibrosis of the lungs. Acute exacerbation of IPF
(AE-IPF) is defined as a sudden acceleration of the disease or an idio-
pathic acute injury superimposed on diseased lung that leads to a
significant decline in lung function. AE-IPF is associated with a high
mortality rate among IPF patients. Since no prophylactic treatments
for AE-IPF have been established, the novel therapeutic strategies are
strongly demanded.
We have previously reported that atrial natriuretic peptide (ANP), an
endogenous peptide produced by the heart, has protective effects
on bleomycin-induced pulmonary fibrosis through vascular endothe-
lial cells in mice. Motivated by the previous findings, we examined
the effects of ANP on AE-IPF models in mice.
In AE-IPF models, we administered LPS (acute exacerbation model)
21 days after bleomycin administration (IPF model) via oropharyngeal
aspiration. ANP (0.5 μg/kg/min) or vehicle was subcutaneously in-
fused via an osmotic mini-pump two days before LPS challenge, and
the infusion continued until the mice were euthanized one day after
LPS challenge. In bronchoalveolar lavage (BAL) analysis, both total
and macrophage cell counts were significantly elevated in the
vehicle-treated group compared to the normal control group. ANP
significantly decreased total and macrophage cell counts compared
to vehicle. Quantitative assessment of the number of inflamed cells,
as determined by Mac3 staining, demonstrated that ANP significantly
attenuated the number of inflammatory cells in the lungs compared
to vehicle. Consistently, ANP reduced the concentrations of IL-1β, IL-
6, KC, MIP-1β, and MCP-1 in BAL fluid compared to vehicle. In sum-
mary, ANP can attenuate acute exacerbation in the lung induced by
LPS in bleomycin-induced pulmonary fibrosis.
Conclusion:
Altogether, we concluded that ANP-GC-A signaling as a promising
target for controlling IPF and AE-IPF.A16
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It is now accepted that inorganic nitrate, through its sequential
chemical reduction to nitrite and then to nitric oxide (NO), provides a
source of NO in the body that exerts a number of important actions
upon the cardiovascular system including blood pressure lowering;
effects that are mediated by cyclic GMP (cGMP). Whilst the second
step of this process is due to the activity of mammalian nitrite reduc-
tases, including xanthine oxidoreductase, the former (i.e. the chemical
reduction of nitrate to nitrite) is critically dependent upon the activity
of commensal bacteria, particularly residing within the oral cavity.
We and others have speculated that the entero-salivary circuit of inor-
ganic nitrate offers an opportunity to target NO/cGMP signalling in the
cardiovascular system in disease via a pathway that circumvents the
classical, but dysfunctional, L-arginine/NO synthase (NOS) pathway. This
proposal stems from observations indicating that supplementation of
inorganic nitrate via dietary means (vegetables, particularly green leafy
vegetables have a high inorganic nitrate content) or through nitrate salt
administration exerts blood pressure lowering, anti-inflammatory and
anti-thrombotic effects in patients with cardiovascular disease. In
addition, evidence suggests that dietary inorganic nitrate not only pro-
vides beneficial effects acutely but that these positive actions are sus-
tained with chronic administration and do not suffer tachyphylaxis. This
difference in pharmacokinetics intimates that unlike the organic ni-
trates, inorganic nitrate provides sustained NO delivery with persistent
administration and thus provides an approach to NO delivery that
might prove useful in the therapeutics of chronic disease. In this pres-
entation, the circuit for bioactivation of inorganic nitrate in the body
and the key role that bacteria play in this process will be addressed. In
addition, clinical studies supporting a role for nitrate bioactivation in
setting blood pressure, and the potential for use of this circuit in the
therapeutics of cardiovascular disease will be described.
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Reactions based on the transfer of one or more electrons from a
donor (reductant) to an acceptor (oxidant) account for many physio-
logically relevant cellular processes. Both reactive oxygen (ROS) and
nitrogen species (RNS) can signal through these reduction/oxidation
(redox) reactions, particularly via reversible interaction with reactive
thiols, namely cysteines. Nitroxyl (HNO) - the one-electron reduction
product of nitric oxide (NO.) - has garnered a lot of attention owing
to its pharmacological properties that are quite dissimilar from those
exhibited by its sibling NO. or other RNS such as nitrite/nitrate. HNO
uniqueness stands out especially in the cardiovascular system, where it
exerts positive effects on contractility and relaxation, while inducing
venous and arterial dilation. These benefits are preserved in failing
hearts that harbour altered redox conditions and perturbed signalling
pathways, such as cAMP/PKA. In fact, there are, at least, four biochem-
ical properties that single HNO out from other modulators of myocar-
dial function, justifying its potential both as a signalling molecule and
therapeutic option. They are its elective, and likely selective thiophilic
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 8 of 35nature, inertness towards ROS, modest reactivity with molecular O2,
and likely the fact that HNO does not interfere with other post-
translational modifications, such as phosphorylation. Accordingly, HNO
donors are currently evaluated for safety and efficacy in patients with
acute decompensated heart failure (ADHF). Notwithstanding, many key
questions still surround HNO biology and pharmacology. First and fore-
most, it is still unclear under which conditions, and where HNO is
formed in the human body (although it is a major gas in the space!).
Equally unknown is what mechanisms eventually cease its signalling,
along with the exact chemical nature of HNO-induced modifications
that pave the way to either signalling or detrimental effects. Finally,
much remains to be discovered in terms of additional HNO biological
actions that may dovetail nicely with already established effects in the
circulation as well as in other compartments. Here, major “knowns” and
“unknowns” about HNO biology and HNO donor pharmacology will be
discussed, and the HNO therapeutic portfolio for ADHF will be com-
pared to current mainstay therapies.
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Protein kinase G (PKG) is subject to complex redox regulation involving
several modes of oxidation, including interprotein disulfide formation
at C42. The C42 disulfide homodimer is associated with targeting and
activation of PKG Iα, which significantly contributes to vasodilation and
blood pressure lowering in response to exogenously applied or en-
dogenously generated oxidants. Interdisulfide-PKG Iα levels were found
to increase in the mouse heart during diastolic stretch, consistent with
evidence that oxidants are produced during myocardial relaxation at
this time. Interdisulfide-PKG Iα selectively targets and phosphorylates
phospholamban at S16, which activates the sarcoplasmic reticulum (SR)
Ca2+ ATPase 2a (SERCA2a) to enhance sequestration of calcium into the
sarcoplasmic reticulum. Consistent with this C42S PKGIα knock-in (KI)
mice that are resistant to kinase oxidation to the interdisulfide state are
hypertensive and have diastolic dysfunction as evidenced by echocardi-
ography and left ventricular Pressure-Volume catheter analysis. Thus, it
is evident that PKG Iα interprotein disulfide formation occurs during
myocardial stretch, and without this mechanism the hearts have im-
paired relaxation during diastole. Given the role for interdisulfide-PKG
Iα in blood pressure-lowering, we assembled and screened a ‘soft-elec-
trophile’ compound library for molecules that would mimic or induce
oxidation of the kinase. We identified a compound which we have
called G1 which induces vasodilation of isolated arterial vessels from
wild type mice, whereas the impact on vessels from KI was significantly
deficient. G1 also lowered blood pressure in an angiotensin II-induced
hypertension model in wild type, but not KI, mice. This provides proof-
of-principle for a new class of anti-hypertensive drugs, which concep-
tionally may also have value in the treatment of diastolic heart failure.
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As a primary receptor of cGMP in mammalian cells, PKG is a cen-
tral mediator of the NO-cGMP signaling pathway that regulates
crucial physiological processes [1-3]. These include smooth muscle
tone, bone growth, nociception, and memory formation. Two
types of PKGs exist, PKG I and II. They display distinct subcellular
localization, tissue expression, and substrates suggesting their
non-redundant cellular functions [4].
Cyclic GMP analogs, 8-Br-cGMP, 8-pCPT-cGMP, and PET-cGMP,
have been widely used for characterizing cellular functions of
PKG I and II isotypes [5, 6]. However, interpreting results ob-
tained using these analogs has been difficult due to their low
isotype specificity. Additionally, the regulatory (R)-domain of
each isotype has two binding sites with different cGMP and
analog binding characteristics [7], making understanding the
molecular basis for isotype specificity of these compounds even
more challenging.
Results:
To determine isotype specificity of cGMP analogs and their
structural basis, we generated the full-length regulatory do-
mains of PKG I and II with each binding site disabled, deter-
mined their affinities for these analogs, and obtain co-crystal
structures of both isotypes bound with cGMP analogs. To dis-
able each site for cGMP binding, we replaced a conserved gly-
cine within each cGMP binding pocket (G182 and G306 in PKG I
and G232 and G356 in PKG II, respectively) with a glutamate.
These mutations are predicted to cause steric hindrance and
charge repulsion with the negatively charged cyclic phosphate
moiety.
Our affinity and activation measurements using competitive sur-
face plasmon resonance and microfluidic mobility-shift assay
show that PET-cGMP and 8-pCPT-cGMP are ~40-50 fold selective
in binding and ~10 fold in activating against each isotype,
whereas 8-Br-cGMP is only ~10 fold selective in binding and ~4
fold in activating PKG II. 8-Br-cGMP and 8-pCPT-cGMP similarly
bind and activate PKG I compared to cGMP (Tables 2). In con-
trast, 8-Br-cGMP and 8-pCPT-cGMP show gradual increases in
both EC50 and KA values for PKG II. Unexpectedly, PET-cGMP
binds and activates PKG II with similar potencies as cGMP, pro-
viding little selectivity against PKG II (Tables 2)
The site-specific mutant data using competitive surface plasmon
resonance suggest that the B-sites provide the high preference
of PET-cGMP in PKG Iβ and the structures of the PKG I and II
CNB-B domains explain why. The crystal structure of PKG I CNB-
B domain bound with PET-cGMP shows that PET-cGMP interacts
with its more open pocket and forms a unique π/π interaction
with Arg285 at β4 (Fig. 1). On the other hand, our structures of
PKG II CNB-B show a more shielded pocket due to the C-terminal helix
(αC-helix) that provides the most of the cGMP specific contacts (Fig. 1).
In particular, our model of the PKG II CNB-B docked with PET-cGMP
shows that Gln335 at the analogous position to Arg285 of PKG I and
Asp412 at the αC-helix causes steric clashes with the PET moiety redu-
cing its affinity for the B-site [8].
Lastly, the site-specific mutant data also suggest that the A-sites are
mainly responsible for the high preference of 8-pCPT-cGMP in PKG II and
the crystal structures of the CNB-A domains explain why. Our structures
of the CNB-A domains of PKG I and II show that PKG II has a larger β5/β6
hydrophobic pocket that can better accommodate a bulky functional
group compared to PKG I, which explains its lower EC50 value [8, 9].
Conclusion:
Our structural and functional results explain selectivity of these
analogs for PKG I and II and provide a starting point for the ra-
tional design of isotype selective activators.
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Fig. 1 (Abstract A19). The crystal structures of carboxyl domains of
PKG I and II explain high selectivity of PET-cGMP for PKG I isotype.
The crystal structure of the PKG I CNB-B bound with PET-cGMP and
the model of the PKG II CNB-B domain docked with PET-cGMP are
shown on the top. PET-cGMP was docked onto the PKG II CNB-B
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PKG I shows a unique π/π interaction between Arg285 and the PET-
moiety (left) explaining its high selectivity for PET-cGMP. In contrast,
Gln335 and Asp412 of PKG II cause steric clashes with the PET-moiety
explaining its low affinity (right). The surface is colored according to
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Acad Sci U S A 2001, 98:10037-10041.Table 2 (Abstract A19). Affinity and activation constants measurements
of PKG I and II for cGMP and analogs
Affinity Measurements of PKG I and II Regulatory Dimers
PKG Iβ
hPKG Iβ
1-351
cGMP 8-Br-cGMP 8-pCPT-cGMP PET-cGMP
WT 163±6 nM
(2)
222±4 nM
(2)
212±20 nM
(3)
3.8±0.4 nM
(2)
G182E 328±6 nM
(2)
765±25 nM
(2)
206±18 nM
(2)
5.8±0.4 nM
(2)
G306E 4.2±0.1 nM
(3)
< 2 nM
(2)
7.7±0.4 nM
(2)
<< 2 nM
(2)
PKG II
hPKG II
41-418
cGMP 8-Br-cGMP 8-pCPT-cGMP PET-cGMP
WT 96±5 nM
(3)
20±2 nM
(3)
5±1 nM
(3)
193±10 nM
(3)
G232E 184±0.1 nM
(2)
11±1 nM
(2)
116±8 nM
(2)
1963±12 nM
(2)
G356E 50±3 nM
(3)
30±2 nM
(2)
≤ 1.1±0.3 nM
(2)
5.3±0.3 nM
(2)
Activation Constant Measurements of PKG I and II Full Lengths
cGMP 8-Br-cGMP 8-pCPT-cGMP PET-cGMP
hPKG Iβ
5-678
370±13 nM
(4)
206±13 nM
(3)
249±17 nM
(3)
18±2 nM
(3)
hPKG II
40-762
257±11 nM
(3)
58±5 nM
(3)
22±3 nM
(4)
225±13 nM
(3)
Footnote:
EC50 and KA values were measured using competitive surface plasmon
resonance and microfluidic mobility shift assay. (n) = Number
of measurements.
charged areas are shown in blue and negatively charged areas are in
red. The surface corresponding to the αC-helix of PKG II CNB-B is
marked with the dotted lineA20
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Biological background:
Mycobacterium tuberculosis escapes killing in human macrophages by
secreting protein kinase G (PknG), which intercepts host signaling to
prevent the fusion of the phagosome engulfing the mycobacteria
with the lysosome. The N-terminal ~75 residues were predicted to
show no regulatory secondary structure (NORS, not present in the
crystal structure shown in Fig. 2) but to harbor the major in vivo
phosphorylation site (T63) and to play a role for PknG regulation by
autophosphorylation in trans. The following rubredoxin-like metal-
binding motif (RD, ~74–147, Fig. 2) makes tight interactions with the
catalytic domain (~148–420) and mediates PknG redox regulation.
Deletions or mutations in the NORS or the redox-sensitive RD signifi-
cantly decrease PknG survival function.
Results and Conclusion:
Here, we present nuclear magnetic resonance (NMR) spectros-
copy, in vitro kinase assay, and molecular dynamics (MD) simula-
tion data that provide novel insights in the regulatory roles of the
NORS and the RD. The NORS region is rather dynamic and appears
indeed to be natively disordered. In agreement with published
data, we observe autophosphorylation only if the NORS region is
present and thus in the NORS region. Phosphorylation in the
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 10 of 35NORS results only in local conformational changes and does not
induce interactions with the following RD. In the crystal structure
(Fig. 2), the reduced, metal bound RD makes tight interactions
with the catalytic domain. Based on NMR structural data, it can
also fold in its absence. The combined NMR-, MD-, and kinase
assay data further suggest that oxidation-induced unfolding of
the RD regulates substrate access to the catalytic domain and
thereby PknG function under different redox conditions, e.g. if ex-
posed to increased levels of reactive oxidative species (ROS) in
host macrophages [2]. We further analyzed the interactions of the
RD with membrane mimetics. Both, the reduced, metal bound
and the oxidized unfolded RD, can interact with micelles and
bicelles, but not liposomes. This may play a role for the observed
membrane localization of PknG.
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Our laboratory have determined that of the 80-90 eukaryotic protein
kinases expressed in the malaria parasite kinome nearly half are es-
sential for the blood stage survival of the most virulent strain of hu-
man malaria, P. falciparum. One of these essential protein kinases is
the cGMP-dependent protein kinase, PfPKG. To determine the cellular
substrates for PfPKG we employed a novel chemical genetic ap-
proach that takes advantage of a change in the gate keeper residue
of PfPKG that renders the kinase insensitive to a inhibitor called com-
pound 1. Using this approach in combination with quantitative glo-
bal phosphoproteomics, the phosphorylation sites on 69 proteins
that are direct or indirect cellular targets for PfPKG were identified.
These PfPKG targets included proteins involved in cell signalling, pro-
teolysis, gene regulation, protein export and ion and protein trans-
port, indicating that cGMP/PfPKG signalling plays a central role in a
number of core parasite processes. We also show that PfPKG activity
is required for parasite invasion. This correlates with the finding that
the calcium-dependent protein kinase, PfCDPK1, is phosphorylated
by PfPKG, as are components of the actomyosin complex, in a man-
ner that provides a mechanistic insight into the essential role of
PfPKG in parasite egress and invasion.
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Background:
Pulmonary hypertension (PH) is a disease of the vasculature of the
airways resulting in vasoconstriction and arterial remodelling, eventu-
ally leading to right ventricle failure and death. cGMP-dependent
protein kinase (PKG) I knock-out mice develop spontaneous PH,
while PKG I protein expression is paradoxically upregulated during
hypoxic PH. Previous work from this laboratory has shown PKG Iα is
susceptible to oxidation, forming a disulfide homodimer associated
with targeting and activation of the kinase that mediates vasodilation
and blood pressure lowering. During acute hypoxia, pulmonary cells
become pro-reducing – which may be anticipated to reduce the
amount of disulfide-PKG Iα and so contribute to acute hypoxic pul-
monary vasoconstriction. In the present study, we investigated the
redox state of pulmonary PKG Iα during chronic hypoxia and its po-
tential role in pathogenesis of hypoxic PH.
Results and Discussion:
Mice were subjected to hypoxia (10% O2), which caused oxidation of
lung PKG Iα as determined at 3 or 28 day time points compared to
basal normoxic levels. The H2O2-producing enzymes NADPH oxidase
4 (NOX4) and extracellular superoxide dismutase (SOD3) were also in-
creased in the lungs as measured at the 28 day time point, thus po-
tentially contributing to PKG Iα oxidation. In addition, the vascular
isoform of cystathionine gamma-lyase (CSE), which produces the
vasorelaxant H2S, was also upregulated at both time points of
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 11 of 35hypoxia. These observations are consistent with PKG Iα oxidation be-
ing mediated by H2O2-induced oxidation of H2S, which generates
pro-oxidising polysulfide species. Interestingly, we observed in-
creased PKG Iα oxidation, as well as NOX4 and CSE upregulation in
lungs from patients with pulmonary arterial hypertension. This sug-
gests that kinase oxidation pathway may be important in the eti-
ology of PH in humans.
To dissect the potential role of oxidised PKG Iα in hypoxic PH we uti-
lised redox dead Cys42Ser PKG Iα knock-in (KI) mice which are resist-
ant to oxidation. We found that the KI mice had increased
pulmonary vascular resistance, elevated pulmonary myosin light
chain phosphorylation, as well as potentiated right ventricular hyper-
trophy and higher right ventricular pressure after 4 weeks of chronic
exposure to hypoxia, as compared to their WT littermates. These ob-
servations were consistent with U-46619-constricted pulmonary ves-
sels from KI mice having impaired vasodilatory responses to H2O2
compared to WT under normoxic condition, despite equal maximal
constriction to the pressor agonist. Our finding suggests that chronic
PKG Iα oxidation, as well as perhaps increased PKG expression, serves
an important novel intrinsic adaptive mechanism to offset increased
pulmonary pressure in PH and thus reduce RV after-load and so limit
progression to right heart failure. Chronic pharmacological inhibition
of CSE with propargylglycine (50 mg/kg/day) potentiated RV pressure
and hypertrophy, as well as attenuated PKG Iα oxidation in the lung
after 2 weeks of chronic hypoxic exposure. In contrast, chronic treat-
ment with the H2S donor sodium hydrosulfide (23 mg/kg/day) or po-
tassium polysulfide (2 mg/kg/day) prevented excessive RV pressure
and hypertrophy after 2 weeks of hypoxia. Preliminary data from ongoing
experiments suggest that this protection provided to WT mice by H2S or
its oxidised variants was not afforded to the Cys42Ser PKG Iα KI.
An unbiased microarray transcriptomic screen revealed an upregula-
tion of pro-growth, extracellular matrix remodelling and endothelial
to mesenchymal transition cellular signalling pathways in response
to early hypoxia (day 3) in the lungs of the redox-dead KI mice com-
pared to WT. Consequently, the KI mice showed excessive musculari-
sation of small pulmonary vessels and enhanced transition of
pulmonary endothelial cells to myofibroblasts after 4 weeks of
chronic hypoxia. Given the important role of PKG I in cell growth and
cancer, these data suggest that hypoxia-induced PKG Iα oxidation
may prevent pulmonary vascular smooth muscle cell proliferation
and/or endothelial to mesenchymal cell transition, in addition to its
pressure-lowering role.
Conclusion:
We conclude that hypoxia-induced NOX4, SOD3 and CSE upregula-
tion may underlie PKG Iα oxidation in this scenario and thus could
mediate endogenous adaptation to PH by inducing phosphorylation
of target proteins involved in lowering pulmonary pressure, resulting
in reduced RV afterload in the setting of PH. This mechanism could
also be relevant to other situations in which occurs PH, including
PAH in human. The redox dead PKG Iα KI mice lack this protective
mechanism and therefore have an exacerbated hypoxic PH
phenotype. Interventions inducing PKG Iα oxidation in the lung,
such as H2S donors or drugs that induce the selective oxidation
of PKG Iα, could be beneficial in the treatment and management
of PAH.
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Background:
Endothelium-derived C-type natriuretic peptide (CNP) plays a funda-
mental role in regulating vascular homeostasis by controlling arterialtone, blood pressure, leukocyte flux, platelet reactivity and the integ-
rity of the vessel wall [1]. However, a physiological role for endogen-
ous CNP in the heart remains to be established. Therefore, we have
utilised two novel mouse strains with endothelium or cardiomyocyte
-specific deletion of CNP to determine if the peptide modulates heart
function under basal conditions and during cardiac stress.
Materials & Methods:
Blood pressure and electrocardiogram (ECG) were assessed by radio-
telemetry. A Langendorff heart model was used to study coronary
vascular reactivity and ischemia-reperfusion (I/R) injury ex vivo. Echo-
cardiography was performed to determine cardiac function at base-
line and following pressure overload (abdominal aortic constriction
[AAC]; 6 weeks) -induced left ventricular hypertrophy/heart failure.
Following AAC, cardiomyocyte hypertrophy and interstitial fibrosis
were determined using immunohistochemistry and qPCR. A subset
of experiments were also repeated in mice with global deletion of
natriuretic peptide receptor C (NPR-C) to delineate the signalling
pathway involved in mediating any cardiac effects of CNP.
Results:
Hearts from endothelium-specific CNP knockout (ecCNP KO) mice ex-
hibited attenuated responses to the vasodilators bradykinin and
acetylcholine compared to wildtype (WT) littermates. Shear-stress in-
duced coronary dilatation (i.e. reactive hyperaemia) was also blunted
in ecCNP KO. Larger myocardial infarct sizes and poorer recovery of
left ventricular contractility were observed in hearts from mice lack-
ing cardiomyocyte-derived CNP (cmCNP KO) following IR injury. Simi-
lar results were found in NPR-C KO mice but not ecCNP KO hearts.
Under basal conditions heart rate, blood pressure and ECG parame-
ters in cmCNP KO mice were not altered. However, during pressure
overload-induced heart failure cmCNP KO mice exhibited greater car-
diac dysfunction and fibrosis than WT littermates; a similar pheno-
type was apparent in NPR-C KO, but not ecCNP KO, animals
subjected to AAC. Furthermore, infusion of CNP via an osmotic mini-
pump reversed cardiac dysfunction following AAC in WT animals, but
had no effect in NPR-C KO mice.
Conclusion:
These data suggest that both endothelial and cardiomyocyte -derived
CNP play distinct but important roles in the heart, governing coronary
vascular tone and the response to pressure overload. These protective
functions are mediated, at least in part, via activation of NPR-C.
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Clinical background:
Achromatopsia (ACHM) is a genetically and clinically well-defined
inherited retinal disorder. Patients with ACHM suffer from severely
impaired daylight vision, characterized by poor visual acuity, photo-
phobia, nystagmus (involuntary rapid eye movements), and lack of
the ability to discriminate colors (Fig. 3). Currently, six disease genes
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 12 of 35have been identified including the two genes encoding the cone-
specific cyclic nucleotide-gated channel subunits CNGA3 and CNGB3.
Results:
We developed a recombinant adeno-associated virus (AAV) vector-
mediated gene supplementation therapy for the treatment of
CNGA3-linked ACHM (ACHM2). The vector expresses full length hu-
man CNGA3 under control of the human, cone-specific cone arrestin
promoter and was packaged with AAV8 capsid. The resulting vector
(rAAV8.CNGA3) was tested for efficacy in the Cnga3 knockout (KO)
mouse model of ACHM2. Toxicity and biodistribution was assessed in
non-human primates (NHP). rAAV8.CNGA3 delivered into the subret-
inal space of Cnga3 KO led to efficient and stable CNGA3 transgene
expression and biological activity as determined by immunohisto-
chemistry and electroretinography, respectively. Up to 1x1012 total
vector genomes (vg) have proven save when delivered into the sub-
retinal space of NHPs with only limited biodistribution and shadding
and minimal signs of inflammation. An interventional phase I/II clin-
ical trial (NCT02610582) was initiated focusing on safety and efficacy
of a single subretinal injection of rAAV8.CNGA3 in patients with
ACHM2 at three different doses: 1x1010, 5x1010, and 1x1011 total vg.
Conclusions:
Although the approach was targeting the central retina and involved
temporal detachment of the fovea/macula, the treatment has proven
to be safe, was well tolerated and did not results in any clinically ap-
parent inflammation or test item related events. Preliminary clinical
data will be discussed.
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patients. Patients with Achromatopsia are unable to distinguish colors,
have markedly reduced visual acuity and are hypersensitive to ambient
light (left panel). The same image of a flower meadow as seen with
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nated proteins that are insufficiently cleared by the ubiquitin prote-
asome system (UPS) contributes to many diseases. However,
therapeutic methods to enhance the UPS and counter proteotoxicity
are lacking. Cardiac infarction is an example of a disorder where ubi-
quinated protein accumulation (UPA) is thought to play a patho-
physiological role. In studies employing a model in which PKG
activation is suppressed in vivo or in vitro, we found this accumula-
tion and attendant myocardial or myocyte toxicity worsened. Activat-
ing PKG in a similar setting was beneficial. An unbiased cGMP-
stimulated phosphoproteome analysis in adult myocytes revealed
Ser20 on carboxyl terminus of the Hsc70-interacting protein (CHIP)
was a novel target of PKG activation. We found suppressing PKG acti-
vation results in reduced CHIP expression in the myocardium and in
myocytes subjected to simulated ischemia. Using gain (S20E) and
loss (S20A) of function phospho-mutants, we found S20E-CHIP mim-
icked PKG protection, reducing UPA and cytotoxicity with ischemia.
The opposite occurred with S20A-CHIP. Intriguing, if S20A was
expressed, PKG activation was unable to rescue the worsened pheno-
type, even though it can still act to blunt other signalling pathways
including enhancement of proteasome protease activity. The molecu-
lar consequence of S20 phosphorylation was an increase of CHIP
binding to its cognate chaperone Hsc70, and stabilization of post-
transcriptional CHIP protein levels. Depressing PKG activity (or using
the S20A mutant) dissociated CHIP from Hsc70, reduced its protein
expression levels, and compromised its capacity to enhance protein
quality control. These data identify PKG-CHIP interactions that control
UPS activity, and provide a new therapeutic avenue to treat diseases
with compromised protein quality control.A26
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In addition to its role as regulator of the chronotropic, inotropic and
lusitropic response to catecholamines, cAMP affects multiple other
functions including, among others, cell growth, metabolism and
death. This complex functional role is achieved via modulation of ion
fluxes at membranes and of myofilament sensitivity to Ca2+ as well
as via regulation of transcription factors and a variety of enzymes
and other targets. A key question remains how coordination is
achieved among the complex cAMP signalling networks. In recent
years we[1-5] and others[6-8] have demonstrated that cAMP signal-
ling is compartmentalised. Compartmentalised signalling allows indi-
vidual GPCRs to generate distinct cAMP pools that, in turn, activate
defined subsets of localized PKA that are tethered in proximity to
specific targets via binding to A kinase anchoring proteins (AKAPs).
Posphodiesterases (PDEs), a superfamily of enzymes that degrade cAMP
and that includes more than 50 isoforms presenting unique regulation
and subcellular localisation features, play a key role in the spatial regula-
tion of cAMP propagation, and regulate cAMP levels within individual
compartments. Thus, displacement of individual PDE isoforms from their
subcellular anchor site results in local elevation of cAMP[5].
Compartmentalisation of cAMP signalling has important implications
for cardiac physiology and pathophysiology[6]. We have recently
demonstrated, for example, that inhibition of PDE2A, but not inhib-
ition of PDE3 or PDE4, results in anti-hypertrophic effects both
in vitro and in vivo[9]. The compartmentalised nature of cAMP signal-
ling prompts the idea that with a detailed understanding of the
organization, regulation and function of individual cAMP compart-
ments it may be possible to target individual cAMP pools, rather than
global intracellular cAMP levels, in order to achieve greater thera-
peutic efficacy and specificity[7].
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The second messenger cGMP serves diverse functions in the cardio-
vascular and neuronal systems. FRET-based cGMP indicators derived
from the cGMP-binding domains of the cGMP-dependent protein
kinase I can be used to visualize cGMP signals in primary cells. How-
ever, expression of FRET-based cGMP indicators in primary cells is
challenging. Therefore, we generated a knock-in mouse line with
stable and ubiquitous expression of a FRET-based cGMP indicator
(cGi500). This indicator with an EC50 for cGMP of 500 nM allows for
the detection of cGMP concentrations between 100 nM and 3 μM.
Using these mice, we analysed cGMP signals in primary neurons, car-
diac cells (myocytes and fibroblasts) and renal glomeruli. In cardiac
cells and renal glomeruli, nitric oxide- and natriuretic peptide-
induced signals were compared and the phosphodiesterases respon-
sible for cGMP degradation were identified. In hippocampal and
cortical neurons, analysis of cGMP signals induced by glutamatergic
agonists revealed that not only NMDA but also AMPA is able to in-
crease cGMP via endogenous nitric oxide formation.
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Introduction:
Cyclic guanosine 3´5´-monophosphate (cGMP) plays a crucial role in
the regulation of multiple physiological processes including the car-
diovascular system [1]. As a consequence of hypoxia in the heart,
maladaptive signaling cascades are activated that can result in car-
diac damage and finally lead to heart failure [2, 3]. However, until
now, cellular responses to hypoxia/reoxygenation (H/R) are stillincompletely understood and little is known about cGMP dynamics
in the context of H/R.
Aims and methods:
It was the aim of this project to study the effects of H/R on cGMP dy-
namics in mammalian cardiomyocytes. Therefore transgenic mice
with cardiomyocyte-specific expression of the cytosolic Förster-reson-
ance energy transfer (FRET)-based cGMP sensor red cGES-DE5 [4]
were used. We performed FRET measurements in single adult cardio-
myocytes exposed to H/R and additionally used a Langendorff sys-
tem for FRET measurements in whole heart.
Results:
In single adult cardiomyocytes exposed to H/R, basal cGMP levels
were increased. This increase was generated during hypoxia and was
maintained during reoxygenation. After H/R PDE3 protein expression
as well as activity were significantly downregulated, whereas RNA ex-
pression level of PDE3 was not significantly changed. At the same
time, protein levels of soluble guanylyl cyclase β-subunit showed a
tendency towards downregulation during H/R.
Our whole heart measurements indicate that there is also an influ-
ence of other cell-types on cGMP dynamics or on cGMP cell-cell
transfer since we could show that cGMP levels increase during an-
oxia and decrease during reoxygenation.
Conclusion:
In conclusion, we found an increase of intracellular cGMP levels in hypoxia.
The development of FRET-based cGMP measurements in single cardi-
omyocytes and whole hearts in the context of H/R should help to
distinguish between direct protective effects on cardiomyocytes and
indirect mechanisms such as cell-cell interactions in cGMP signaling
during and after H/R. This offers great opportunities to dissect the mo-
lecular mechanism of cGMP signaling regulation during ischemic injury.
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Background:
Guanylate cyclases are important drugs targets for several disorders, in-
cluding cardiovascular, pulmonary and renal diseases. Only heme-
dependent stimulators and heme-independent activators of soluble gua-
nylate cyclases (sGCs) have been amply studied, although even in this
case their mechanism of action is unclear. We have recently described
the potential binding site of heme-dependent stimulators [1]. In this
study, we are: first, investigating the mechanism of action of these heme-
dependent stimulators of sGCs, and, second, searching for new modula-
tors of membrane guanylate cyclases (mGCs). In both cases, we are using
the recently available structural data for this class of enzymes.
Methods:
Basically, the general procedure includes first comparative modelling of
the target protein (based on the satisfaction of spatial restraints),
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 14 of 35docking of a subset of compounds pertaining to the ZINC-database
(Zbc-ZINC Biogenic compounds; 180,313 molecules) to several confor-
mations of the potential “druggable” sites in the proteins of interest,
and selection of the compounds with the best score for site specificity.
Drugs with poor site and protein specificity are discarded. Molecular dy-
namics is used for the selection of protein conformations submitted to
drug docking (after evaluation of the volume of the cavities during the
whole simulation) and to analyze the time-dependent structural
changes evoked by the best-scoring compounds. Ligand binding affin-
ities are evaluated by the Linear Interaction Energy (LIE) method [2].
Results and conclusions:
Molecular dynamics of the catalytic domain of human sGC (both, in
its inactive and active conformations) in the presence or absence of
YC-1 are underway to identify its possible mechanism of action. On
the other hand, different sites (including catalytic and receptor do-
mains) of the atrial natriuretic peptide receptor 1 have been submit-
ted to structure-based virtual screening (SBVS) in order to find new
modulators of mGCs. Preliminary results of this screening are shown
on Table 3 and Fig. 4 for the receptor-binding site.
Computational structure-based approaches can be very useful in the
understanding of the mechanisms of drug function and in the search
of new modulators of important drug targets. The new ligands thus
discovered could be of invaluable help to dissect the role of these
proteins in their physiological contexts.
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virtual screening (SBVS) for modulators of NPRA
Compounds Predicted binding affinity
(kcal/mol)
z00_092002 -11.8
z00_090230 -11.7
z00_032491 -11.7
z00_032002 -11.6
z01_003076 -11.5
z01_031318 -11.5
Fig. 4 (Abstract A29). Binding sites of the drugs with the best score in
a structure-based virtual screening (SBVS) for modulators of NPRA.
a chains A and B of the receptor domain of human NPRA (in a surface
representation; mauve and blue) with bound ANP (in a licorice
representation; red); (b) chain B (in this view chain A has been eliminated
for simplicity) with ANP and the six drugs with the best score (see Table
3) in a preliminary SBVS (in sphere representations; green).A30
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Background:
Natriuretic peptide receptor-B (NPR-B; GC-B) stimulation by C-type
natriuretic peptide (CNP) causes a lusitropic and negative inotropic
response, through cGMP-mediated phospholamban (PLB) and tropo-
nin I (TnI) phosphorylation. Despite similar increases in cGMP, these
effects are not mimicked by NPR-A (GC-A) stimulation by brain natri-
uretic peptide (BNP). Thus, the mechanisms of the differential cGMP
signalling and compartmentation remain unclear.
Objective:
Clarify the organization of functional cGMP compartments and the
role of phosphodiesterases (PDEs) in both neonatal and adult rat car-
diac myocytes.
Methods and Results:
In ventricular strips, NPR-B-stimulation induced a lusitropic response
and negative inotropic response that was enhanced by inhibition of
PDE3. Fluorescence resonance energy transfer (FRET)-based sensors
for cGMP subcellularly targeted to proteins that regulate inotropic re-
sponses (TnI and PLB) were constructed. Measurements of subcellular
changes in single cardiac myocytes revealed that NPR-A- and NPR-B-
stimulation increased cGMP near PLB, whereas only NPR-B-stimulation
increased cGMP near TnI. PDE2 and PDE3 regulated cGMP in both com-
partments. By combining scanning ion conductance microscopy (SICM),
FRET and local receptor stimulation, we demonstrate that NPR-B recep-
tors both in the T-tubules and on the cell crests are able to increase
cGMP similarly near both TnI and PLB.
Conclusions:
NPR-A receptors increase cGMP only near PLB and does not
modify lusitropic or inotropic responses. The cGMP-mediated
lusitropic and negative inotropic responses generated by NPR-B
in cardiac myocytes is compartmentalized near both TnI and
PLB. The developed targeted sensors are novel tools to
characterize the cGMP compartments that regulate inotropic and
lusitropic responses.
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Background:
Lung fibrosis is a chronic disease with a median survival of three
years. Underlying mechanisms are not fully understood and effective
therapies are lacking. During fibrosis, myofibroblasts are responsible
for an excessive production and deposition of extracellular matrix
(ECM) proteins and collagen. As consequence, functional tissue is re-
placed by scar tissue. The origin of myofibroblasts remains unre-
solved and pericytes have been implicated as a source of
myofibroblasts. NO-sensitive guanylyl cyclase (NO-GC), the receptor
for NO, has been recently shown by our group to be highly
expressed in retinal pericytes. Therefore, we hypothesized NO-GC
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 15 of 35expression in lung pericytes and a potential modulation of fibrotic
processes by the NO/cGMP cascade.
Methods:
To investigate a possible participation of NO-GC in lung fibrosis we
used our general KO mice (GCKO). Expression of Cre recombinase
under the control of the SMMHC promotor led to deletion of NO-GC
in SMC but surprisingly also in lung pericytes; therefore, we used the
'smooth muscle cell-specific' KO mice as model for pericyte-directed
NO-GC deletion. Fibrosis was induced by a single dose of bleomycin
(2 U/kg) via intratracheal instillation. 21 days after instillation lungs
were harvested. Measurements of dry lung weight and collagen con-
tent were used to evaluate fibrotic responses. Immunohistochemistry
was performed to characterize pericytes and lung fibrosis.
Results:
In fact, NO-GC expression can be detected in lung pericytes by colo-
calization with established pericyte markers PDGFRβ and desmin.
Healthy lungs did not express αSMA, a typical marker of fibrosis.
Bleomycin treated mice developed fibrosis shown by an increase in
lung dry weight and collagen content. Both parameters were further
elevated in GCKO mice and in animals deficient in pericyte-NO-GC
compared to control animals. In control mice, fibrotic areas were de-
fined by cells expressing PDGFRβ and αSMA without NO-GC expres-
sion. In GCKO, fibrotic areas were bigger and more diffuse compared
to control animals.
Conclusion:
Absence of NO-GC leads to a deterioration of bleomycin-induced
lung fibrosis in mice. Thus, NO/cGMP signalling appears to be pro-
tective in the development of lung fibrosis.
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Introduction:
Sildenafil and tadalafil are phosphodiesterase 5 (PDE5) inhibitors
widely used as therapy in erectile dysfunction and pulmonary hyper-
tension. Their mechanism of action is the elevation of intracellular
cyclic guanosine monophosphate (cGMP) by inhibiting the break
down by PDE5. cGMP regulates different processes like smooth
muscle relaxation and platelet aggregation [1]. Binding of cGMP to
the allosteric site of PDE5 causes a conformation change in the cata-
lytic site of the enzyme, enhancing the binding affinity of PDE5 in-
hibitors [2-4]. Using isolated and/or recombinant PDE5, it has been
demonstrated that cGMP can increase the affinity of this enzyme for
sildenafil and tadalafil [5, 6], but none of them investigated the influ-
ence of this changed affinity on intracellular concentrations of PDE5
inhibitors.
Objectives:
The aim of this work was to demonstrate that the change of PDE5 af-
finity for PDE5 inhibitors provoked by cGMP leads to higher intracel-
lular concentrations of these compounds. Platelets - possessing the
entire pathway - were used as a cell system.
Materials and methods:
Isolated and washed platelets were incubated with sildenafil or tada-
lafil at different concentrations and for a range of time intervals with
or without DEA NONO-ate as an NO donor. Intracellular sildenafil and
tadalafil concentrations were quantified using ultra performance
chromatography coupled to mass spectrometry methods and intra-
cellular cGMP was measured with a commercial ELISA assay.Results:
Intracellular cGMP concentrations increased when samples were
treated with sildenafil with or without DEA NONO-ate (5 μM). Silden-
afil was avidly taken up into platelets leading to substantially higher
intracellular than extracellular concentrations with up to 4-fold higher
concentrations in the DEA NONO-ate treated samples. Regarding
time dependency a plateau was reached after 10 min. The results ob-
tained for tadalafil were similar to those for sildenafil aside from
some aspects. A plateau was reached only after 30 min, intracellular
accumulation was considerably higher than for sildenafil, and the ef-
fect of DEA NONO-ate was less pronounced.
Conclusion:
Sildenafil and tadalafil both accumulate extensively inside platelets.
cGMP concentrations present in the cell influence accumulation most
likely by changing the affinity of PDE5 inhibitors for PDE5.
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Background:
Regulation of gastrointestinal motility is complex and involves both
excitatory and inhibitory neurotransmission. A very important inhibi-
tory neurotransmitter is nitric oxide (NO). In the GI tract, NO-sensitive
guanylyl cyclase (NO-GC), is the main receptor for NO, which leads to
generation of cGMP. It is expressed in several cell types such as
smooth muscle cells (SMC) and interstitial cells of Cajal (ICC). Cell-
specific knockout mice for NO-GC revealed NO-GC as an intricate
modulator of spontaneous contractions in the colon and specified
the role of SMC and ICC in the regulation of murine colonic motility.
Methods:
This study focuses on the role of NO-GC in murine colonic motility.
We used isometric force studies to record contraction pattern of co-
lonic circular muscle rings from global NO-GC knockout (GCKO) and
cell-specific knockout mice lacking NO-GC specifically in SMC or ICC.
Moreover, video recordings of whole colon preparations were used
to generate spatiotemporal maps, in order to evaluate the contrac-
tion pattern and propagation characteristics of the knockout mice.
Outflow measurements gave detailed information about the effi-
ciency of the propulsive contractions. Spatiotemporal maps enable
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 16 of 35the analysis of long distance contractions (LDC), the strongest pro-
pulsive motor pattern in the mouse colon.
Results and conclusion:
Isometric force studies of colon rings showed three different contractions.
We recorded continuous small high frequency contractions, which were
interrupted by bigger ‘intermediate contractions’, as well as, periodic
‘giant contractions’ which are characterized by a strong tonic contraction
with superimposed ‘ripples’. Our results reveal a modulatory role of cGMP
on intermediate and giant contractions via SMC and ICC.
Furthermore, whole colon preparations revealed cGMP as an import-
ant component of the neuronal circuitry that orchestrates the LDC,
which is most likely the mouse equivalent of the High Amplitude
Propagating Contraction of the human colon. Without cGMP, the fre-
quency of LDC increases. Moreover, the LDC becomes less effective
as shown by an altered LDC topography. This is likely a result of dis-
turbed NO/cGMP signalling in ICC.
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Pancreatic cancer has the highest cancer mortality rate of 93%. Only
57% of pancreatic cancer patients live up to 6 months and only 15% of
patients live over a year and a half. However, the effective therapies for
pancreatic cancer are lacking. T-type calcium channels (transient open-
ing calcium channels) are normally located within the brain, peripheral
nervous, cardiovascular, and endocrine systems. Overexpression of T-
channels in different tumor types has recently gained attention; how-
ever, the role for these channels in pancreatic cancer is not well ex-
plored. NNC 55-0396 is an analog of mibefradil (Ro 40-5967) with
higher selectivity, enhanced potency and reduced side effects. It has
been suggested that NNC 55-0396 can permeate through the plasma
membrane and block T-calcium channels, however, the signaling path-
ways underlying its anti-cancer activity is unknown (1). Our studies with
in four pancreatic cancer cell lines (Pa-TU-8988, Panc-1, YAPC, BxPC-3)
showed that T-channel subtype Cav 3.1 (α1G) is expressed in all cell
lines, whereas Cav 3.2 (α1H) only in Panc-1. The α1subunit is the pri-
mary subunit that forms the transmembrane pore of the channel. NNC
55-0396 treatment inhibited proliferation of all cell lines. The silencing
Cav 3.1 by using siRNA CACNA1G in Pa-TU-8988 cells resulted similar
proliferation inhibition. Cell cycle analysis in Pa-TU 8988 synchronized
cells treated with NNC 55-0396 (5μM) revealed a T-channel blocker-
induced G1 arrest. Thus, we further verified the expression of key genes
involved in cell cycle regulation. The cyclin-dependent kinases 2 (cdk-2)
and 6 (cdk-6) were significantly decreased by 0.56- and 0.38-fold, re-
spectively while the cdk inhibitor p21 (CDKN1A) was markedly in-
creased by 2.5 fold after treating with NNC 55-0396 (5μM, 24 hours). No
significant difference was observed in cdk 4 gene expression. Similar re-
sults were observed with Western blots of CDK2, 6 and p21 Since the
p21WAF1/Cip1 (p21) protein is an inhibitor of cyclin-dependent kinases,
we also checked other pancreatic cells and observed that the T-
channel blocker increased p21 expression in all cell lines. The cyclin-
dependent kinase inhibitor p21 is a major effector of the tumor sup-
pressor p53. However, T-Ca2+ channel blocker promoted p21 expres-
sion in both p53-positive (Panc-1, BxPC-3) and p53-deficient (Pa-TU-
8988) cells (2), and inhibited proliferation of all tested cell lines. We
propose that p21 can be activated independently of p53 in pancreatic
cancer cells. T-type Ca2+ channel blocker may exerts transcriptional
regulation of p21 directly or via either PKG I or HDAC pathways in pan-
creatic cancer cells.Conflict of interest
authors do not have a potentially perceived conflict of interest.
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Arterial hypertension is an increasingly prevalent condition that predis-
poses an individual to increased risk of cardiovascular disease and mor-
tality. Despite the availability of antihypertensive drugs, many patients
have high blood pressure that is resistant to current treatments. The dis-
covery that cGMP-dependent protein kinase 1α (PKG1α) intermolecular
disulfide formation contributes to oxidant-induced or endothelium-
derived hyperpolarisation factor-dependent vasodilation [1,2], highlights
a new mechanism that could be targeted therapeutically to lower blood
pressure in patients resistant to current therapies. Such drugs may also
offer a new, complementary first-line therapy against hypertension.
Here we developed a novel drug assay to screen a library of small elec-
trophilic compounds, to find those that covalently target cysteine 42 of
PKG1α to mimic or induce disulfide activation. 12 candidates identified
in this screen were subsequently tested for their ability to relax mesen-
teric vessels isolated from wild-type mice. Those that successfully re-
laxed mesenteries were re-tested in vessels from wild-type and
concomitantly compared to those isolated from C42S PKG1α knock in
(KI) mice. This led to the identification of a hit compound, which we
named G1 that induced relaxation of wild-type mesenteric vessels
(EC50 = 3.9 ±0.65uM), but to a lesser extent those isolated from C42S
PKG1α KI mice (EC50 = 37 ±11.4uM). Furthermore, feeding of G1 (20
mg/kg for 4 days) lowered blood pressure in telemetered angiotensin-II
hypertensive wild-type mice. This ability of G1 to lower blood pressure
was absent in hypertensive C42S PKG1α KI mice, thus confirming
selectivity for its mechanism of action. In summary, we have identi-
fied the first in a new class of antihypertensive drug that with fur-
ther development, could be used clinically to lower blood pressure
as a first line therapy or perhaps to treat patients resistant to
current interventions.
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FRET-sensors (Fluorescence Resonance Energy Transfer) have been
widely used to detect protein-protein interaction, conformational
changes of proteins or to monitor levels of cyclic nucleotides
(CNs). Particularly, several cAMP and cGMP FRET sensors have
been developed and shown to be valuable tools for determining
spatial and temporal intracellular signaling. Our aim is to monitor
the dynamic changes of cGMP in specific sub-cellular microdo-
mains in cardiac myocytes. Here, the concentration of cGMP is
low, and there are few current cGMP-sensors that can monitor
the low cGMP concentrations seen after guanylyl cyclase activa-
tion. In the current study, we wanted to construct novel FRET
sensors with high affinity for cGMP that can measure temporal
and spatial signaling of guanylyl cyclases.
Methods:
We constructed novel cGMP sensors based on cGMP binding do-
mains from Plasmodium falciparum (PfPKG) and human (PKG I
and PKG II). The binding domains were sandwiched between
FRET pairs, either cyano (CFP) and yellow (Venus) or blue (T-sap-
phire) and red (Dimer2) fluorescent proteins. To improve affinity
and selectivity (against cAMP), mutations in the cGMP-binding
pocket improved affinity and also selectivity. All sensors were
expressed in HEK293 cells and FRET efficacy was determined ei-
ther in vitro or in intact cells stimulated with an NO donor (stim-
ulates soluble guanylyl cyclase).
Results:
We designed three sensors with high affinity (~10 nM) for cGMP and
high selectivity towards cAMP (up to 1.000 fold). All sensors yielded a
large dynamic range (10-20 % change in FRET) and responded to
NO-donor in HEK293 cells.
Conclusions:
The new sensors based on modified cGMP binding domains from
PKG I has the ability to detect cGMP with high affinity and se-
lectivity. We termed the sensor with highest selectivity “ScGI sen-
sor” (Selective cGMP-dependent protein kinase I sensor) and
believe it will be a valuable tool to unravel spatial and temporal
cGMP-mediated intracellular signaling in cardiac myocytes.
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Background:
Although nitroxyl (HNO) is produced endogenously, with pharmaco-
logical donors showing broad therapeutic promise, its mechanisms
of action is not fully elucidated.
Methods and Results:
Mass spectrometry and site-directed mutagenesis showed that the
chemically distinct HNO donors 1-nitrosocyclohexyl acetate or
Angeli`s salt each induced disulfides at disparate sites within cGMP-
dependent protein kinase I-alpha (PKGIα). These included interdisul-
fide between Cys42 of the two identical subunits of the kinase, as
well as a previously unobserved intradisulfide between Cys117 and
Cys195 in the high affinity cGMP-binding site. Kinase activity was
monitored in cells separately transfected with wildtype (WT), Cys42-
Ser or Cys117/195Ser PKGIα that cannot form the inter- or intradisul-
fide, respectively. This revealed HNO enhanced WT kinase activity, an
effect significantly attenuated in inter- or intradisulfide-deficient
PKGIα. Cys42/117/195Ser PKGIα was completely resistant to HNO-
induced activation. To investigate whether the intradisulfide modu-
lates cGMP binding, real-time imaging was performed in vascular
smooth muscle cells expressing a FRET-biosensor comprising the
cGMP-binding sites of PKGIα. HNO induced FRET changes similar to
those elicited by an increase of cGMP, suggesting that HNO-induced
intradisulfide formation is associated with activation of PKGIα. Con-
sistent with the intradisulfide lowering affinity for its classical second
messenger activator, cGMP was unable to potentiate HNO-
intradisulfide induced PKGIα activity. Intradisulfide formation in
PKGIα correlated with enhanced HNO-mediated vasorelaxation in
mesenteric arteries in vitro and arteriolar dilation in vivo in mice.
Conclusion:
We conclude that HNO induces an intradisulfide in the high affinity
cGMP-binding site of PKGIα, inducing the same effect as cGMP bind-
ing, namely kinase activation and thus vasorelaxation.
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Cyclic GMP regulates multiple functions in the cardiovascular system. It is
generally accepted that vascular smooth muscle cells (VSMCs) can gener-
ate cGMP through NO-activated soluble guanylate cyclase as well as
transmembrane guanylate cyclases GC-A and GC-B that are stimulated
by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP),
respectively. Studies with atherosclerotic mice in which either NO-
activated guanylate cyclase or cGMP-dependent protein kinase I had
been deleted suggest that cGMP signaling regulates dynamic changes of
VSMC growth and phenotype (contractile vs. synthetic) during vascular
remodeling. However, the distribution and function of NO-, ANP-, and
CNP-responsive cells in a given population of VSMCs is not clear. Here,
we used transgenic cGMP sensor mice that express the fluorescence res-
onance energy transfer-based cGMP sensor cGi500 to characterize cGMP
responses in live VSMC populations at the singe-cell level. In primary
VSMCs isolated from ubiquitously expressing cGi500 mice, we observed a
strong heterogeneity of cGMP signals triggered by ANP, CNP, or the NO-
releasing compound DEA/NO. Interestingly, differential cGMP responses
were associated with specific VSMC phenotypes. Contractile VSMCs (de-
fined by strong expression of αSMA and SM22α) responded stronger to
ANP than to CNP, while synthetic VSMCs (defined by weak expression of
αSMA and SM22α) responded stronger to CNP than to ANP. Passaging or
growth on fibronectin, maneuvers known to promote the synthetic VSMC
phenotype, increased the fraction of CNP-responsive cells. To confirm
that the CNP-preferring cells originate from smooth muscle cells, we iso-
lated VSMCs from transgenic mice that expressed the cGi500 sensor spe-
cifically in smooth muscle cells [SM22Cre x R26-CAG-mT/cGi500(L2)].
These cultures also contained a heterogeneous population of ANP- and
CNP-preferring cells demonstrating that different VSMC phenotypes vary
in their combination of cGMP signaling components. In line with this con-
cept, experiments with VSMCs expressing β-galactosidase under the con-
trol of the GC-B promoter indicated that expression of the CNP receptor
parallels the development of the synthetic VSMC phenotype during cell
culture. To test the relevance of our in vitro findings for the in vivo situ-
ation, we measured cGMP signals in aortae of healthy cGMP sensor mice.
These aortae showed cGMP responses to ANP and NO, but not to CNP,
supporting the hypothesis that CNP-responding synthetic VSMCs develop
in vivo only under pathologic conditions such as atherosclerosis. In the fu-
ture, we will employ biosensor technology to further investigate the link
between CNP-induced cGMP signaling, VSMC plasticity and vascular dis-
ease under close-to-native conditions to gain novel insights into human
cardiovascular disease states.
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It is well known that NO supplied by the endothelium activates NO-
sensitive guanylate cyclase (NO-GC) in platelets, resulting in an in-
crease in intraplatelet cGMP. However, the spatiotemporal dynamics
of cGMP signals in platelets and their functional relevance during
hemostasis and thrombosis are largely unknown. Here, we used
FRET-based cGMP sensor mice for visualization of platelet cGMP sig-
nals in real time during thrombus formation ex vivo and in vivo. The
cGMP concentration was then correlated with functional parameters
such as platelet aggregation and thrombus growth. As expected, NO
triggered strong cGMP elevations in platelet thrombi formed under
flow in vitro. Surprisingly, we found that NO-induced cGMP signals in
platelets were dramatically increased by fluid flow/shear stress. Sim-
ultaneous measurements of cGMP and Ca2+ revealed that the con-
centrations of these two second messengers had an inverse
relationship. In the presence of NO, application of flow increased
cGMP and suppressed Ca2+ signals. Furthermore, cGMP inhibited
platelet adhesion to fibrinogen and fibronectin in vitro. To test the
in vivo relevance of our findings, we induced thrombosis in platelet-
specific cGMP sensor mice by mechanical or laser-induced injury of
cremaster arterioles and monitored cGMP during thrombus forma-
tion by intravital FRET imaging. These experiments showed that
cGMP was indeed elevated in platelets during thrombus growth
in vivo. Experiments with platelet-specific NO-GC knockout mice vali-
dated the FRET/cGMP measurements and showed that flow-
mediated cGMP signaling limits thrombosis. Taken together, this
study has discovered NO/cGMP signaling as a new mode of platelet
mechanotransduction. We propose a revised model for the role of
cGMP signaling in thrombosis. In this model an increase in shear
stress during thrombus formation acts as an auto-regulatory brake to
prevent thrombus overgrowth and vessel occlusion via an increase in
cGMP followed by a decrease in the intraplatelet Ca2+ concentration.
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Background:
Protozoan parasites of the subphylum Apicomplexa are significant
threats to human and animal health. Malaria is still one of the most
threatening infectious diseases worldwide [5,8]. In particular, treat-
ment of malaria has been hampered by drug resistance. Therefore,
the development of innovative therapies with novel drug targets is
needed. The most dangerous and deadliest variant of malaria is
caused by protozoans of the Plasmodium falciparum, which are trans-
mitted by the female Anopheles mosquitoes.
Previous studies revealed that P. falciparum cGMP-dependent protein
kinase (PfPKG) has three functional cGMP (CNB-A/B/D) and one de-
generate (CNB-C) binding site [2,3]. PfPKG is crucial for both sexual
and asexual proliferation in the mosquito and the human host
[1,5,7,8]. Overall sequence and domain organisation of PfPKG signifi-
cantly differ from mammalian PKG representing a strong drug target
for malaria. However, the regulation mechanisms of PfPKG are largely
unknown. Our previous studies demonstrated that the C-terminal
CNB-D is most important for the activation of PfPKG [3,4]. Most of
protein kinases have an N-terminal amphipathic helix (A-helix)
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 19 of 35shielding a hydrophobic surface of the catalytic domain. Although
the A-helix has a highly conserved structural motif of serine/threo-
nine kinases, its functional role in activation and regulation is not
known. The crystal structure of PfPKG reveals that the αC-helix of the
CNB-D corresponds to this structural motif. Therefore, we focused in
particular on different CNBs and the catalytic domain to investigate
the activation mechanism of PfPKG.
Results:
To investigate the activation mechanism of PfPKG, we studied cGMP
binding and activation of various deletion constructs using fluores-
cence polarization (FP) and a microfluidic mobility-shift assay (MSA).
Our results showed differences in the activation mechanism of PfPKG
compared to mammalian PKG. Strikingly, our measurements showed
that a deletion construct (residues 401-853) only containing CNB-D
and catalytic domain remains inactive without cGMP and becomes
active in the presence of cGMP despite the missing an N-terminal
autoinhibitory sequence (AS). Furthermore, several deletion con-
structs of the PfPKG were generated, in which the individual CNBs
were sequentially deleted: PfPKG 32-853 (without AS), PfPKG 158-853
(without AS and CNB-A), PfPKG 275-853 (without AS and CNB-A/B)
and PfPKG 401-853 (CNB-D with kinase domain). Analogously to
PfPKG 401-853, all deletion constructs revealed a low basal activity
and can be activated 20-25-fold by cGMP suggesting that inhibition
of activity may not depend on the interaction between the AS and
the catalytic domain. While these deletion constructs showed similar
activation constants (KA about 300 nM) compared to the full length
PfPKG, the Hill’s coefficient changed from 1.7 (PfPKG 32-853) to 0.7
(PfPKG 401-853) indicating that CNB-A and CNB-B are required for
positive cooperativity.
Structural comparison of PfPKG in inactive and active conformations
suggested that three amino acids are crucial in stabilizing different
conformation of the αC-helix. The inactive conformation showed that
an arginine (R528) of the αC-helix forms a hydrogen bond with an as-
partate (D597) in the catalytic domain. The cGMP binding to the
CNB-D displaces R528 towards the cGMP binding pocket and R528
interacts with a tyrosine residue (Y480) instead forming a stable salt
bridge. Our data show that mutating these residues in the deletion
mutant (PfPKG 401-853) increases activation constant without chan-
ging its affinity for cGMP. In comparison to wild type (PfPKG 401-
853), single mutant constructs (Y480F, R528K and D597N) have
similar affinities (EC50 about 40 nM) for cGMP. However, Y480F muta-
tion showed a 5-fold increased KA-value (about 1500 nM) and R528K
as well as D597N a 6-fold decreased KA-value (about 70 nM) com-
pared to wild type. In contrast to wild type (PfPKG 401-853), R528K
has a great impact on the specific activity (about 0.3 vs. 5-6 U/mg).
Conclusion:
Our data highlight the critical role of the CNB-D domain in activation
and regulation of PfPKG. Furthermore, CNB-D is essential for the
function and the stability of the catalytic domain. cGMP binding to
the CNB-D domain causes a conformational change in particular in
the αC-helix, which keeps the catalytic domain to an active conform-
ation. A unique salt bridge between R528 of the αC-helix and Y480
of the CNB-D domain stabilizes PfPKG in an active conformation. Our
results clearly demonstrate differences in the activation mechanisms
between PfPKG and human PKG suggesting that PfPKG can be differ-
entially targeted.
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Background:
PAH is a chronic condition with a poor prognosis characterized by in-
creased pulmonary vascular resistance. Riociguat, a soluble guanylate
cyclase stimulator, is the first member of this novel class of PAH ther-
apies. In the 12-week PATENT-1 study, riociguat significantly im-
proved 6-minute walking distance (6MWD), and other secondary
endpoints in patients with PAH. We present analyses from the long-
term PATENT-2 extension study and analyses of correlation between
efficacy endpoints and long-term outcomes.
Methods:
PAH patients who were treatment-naïve or pretreated with
endothelin receptor antagonists or prostanoids entered PATENT-2
after completing PATENT-1 without ongoing riociguat-related ser-
ious adverse events (SAEs). All patients received riociguat indi-
vidually adjusted up to 2.5 mg three times daily. Primary
endpoints were safety and tolerability; secondary endpoints in-
cluded 6MWD, World Health Organization functional class (WHO
FC), N-terminal prohormone of brain natriuretic peptide (NT-
proBNP), survival, and clinical worsening-free survival. Correlation
between efficacy parameters and long-term outcomes was
assessed using Kaplan–Meier analyses and a Cox proportional-
hazards regression model.
Results:
Of 405 patients completing PATENT-1, 396 (98%) entered PATENT-2.
At this cut-off (March 2014), 275 (69%) patients were ongoing, 307
(78%) had received ≥2 years of treatment, and 13 (3%) had switched
to the commercial drug. At 2 years of PATENT-2, 258/307 (84%) pa-
tients were receiving the maximum riociguat dose of 2.5 mg tid, 31/
307 (10%) were receiving 2 mg tid, 12/307 (4%) were receiving 1.5
mg tid, 3/307 (1%) were receiving 1 mg tid, and 3/307 (1%) were re-
ceiving 0.5 mg tid. Riociguat was well tolerated; 11% of patients
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 20 of 35withdrew due to adverse events (AEs). There were 13 (3%) drug-
related SAEs of syncope and 4 (1%) drug-related SAEs of pulmonary
bleeding. All SAEs reported were within the range of the known
safety profile for riociguat. At 2 years, mean±SD 6MWD increased
from PATENT-1 baseline by +47±85 m (n=296) and WHO FC im-
proved/stabilized/worsened in 33/58/9% of patients (n=306). At 2
years, survival was 93% and 17% of former therapy-naïve patients
were receiving additional PAH therapy. Measurements of 6MWD,
WHO FC, and NT-proBNP at baseline and after 12 weeks of treatment
with riociguat correlated significantly with long-term survival and
clinical worsening-free survival.
Conclusions:
Riociguat has a good long-term safety profile and shows sustained
clinical effect for up to 2 years in PAH patients. The correlation of
6MWD, WHO FC, and NT-proBNP with long-term survival and clinical
worsening-free survival emphasizes the prognostic value of 6MWD,
WHO FC, and NT-proBNP for PAH patients.
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The NO/cGMP cascade is essential for the regulation of many physio-
logical functions in the pulmonary system. NO-sensitive guanylyl cy-
clase (NO-GC) has traditionally been purified from lung due to its
very high expression level compared to other organs. Up to date the
exact identity of cell types expressing NO-GC in the lung are unclear.
Methods:
We used immunohistochemistry to localize NO-GC in perfusion-fixed
mouse lung using a home-made antibody against the β1 subunit of
NO-GC. Global NO-GC knockout (GCKO) and cell-specific models
were used to prove the specificity of the immuno-signals. Several
markers specific for lung cells, e.g. smooth muscle cells, fibroblasts,
pericytes were used. In addition, we used Cre recombinase-mediated,
cell-specific expression of the reporter dye tdTomato.
Results and Conclusion:
NO-GC is expressed in bronchial and vascular smooth muscle
cells indicated by co-localization with the smooth muscle cell
marker αSMA. In addition, NO-GC is also strongly expressed in
pericytes as determined by co-staining with platelet-derived
growth factor receptor ß (PDGFRß). Pericytic expression of NO-
GC was corroborated by the use of another pericyte marker,
desmin. These findings were confirmed with animals expressing
the fluorescent dye tdTomato. NO-GC is co-localized with tdTo-
mato expressed under the control of PDGFRß- and NG2-
promotor, both markers for pericytes. Surprisingly, a subgroup of
these NO-GC-positive pericytes also express smooth muscle my-
osin heavy chain (SMMHC) thought to be specific for smooth
muscle cells. In conclusion, NO-GC is expressed in SMC and peri-
cytes of the lung.
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Diabetes mellitus is the world leading cause of functional kidney im-
pairment. In adults with diabetes the risk of end-stage renal disease
(ESRD) is up to 10 times higher than in those without. 30-40% of pa-
tients develop a diabetic nephropathy (DN) as a long-term complica-
tion of diabetes, which might require dialysis and renal replacement
therapy.[1,2]
A specific therapy doesn’t exist so far, because the underlying mech-
anisms are still not completely understood.
However, many intracellular processes are already published,
which might be involved in the pathogenic mechanisms of dia-
betic nephropathy, e. g. generation of reactive oxygen species
(ROS) or advanced glycation end products (AGEs), activation of
PKC or the JAK/STAT pathway.[3]
In this work, we want to find out the role of the cGMP-
dependent protein kinase I (cGKI) in the development of diabetic
nephropathy and if the NO/sGC/cGKI pathway could be a poten-
tial therapeutic target.
Therefore, we established a cell culture model with primary mur-
ine mesangial cells, which were incubated under normal glucose
(8 mM D-Glucose) and high glucose (25 mM D-Glucose) condi-
tions to simulate the blood glucose levels in diabetes. The cells
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 21 of 35were further treated with 1 mM 8-Br-cGMP to activate the cGKI
signalling.
In our model, we confirm previously published effects of high
glucose concentrations on Thrombospondin-1 (TSP-1) expression,
an important regulator of transforming growth factor (TGF)-β.[4]
TSP-1 expression is upregulated under high glucose conditions,
but additional incubation with 8-Br-cGMP retains the protein ex-
pression equally to normal glucose conditions. Moreover, we
show the same effect on Smad-2 expression, a protein which acts
as a transcription factor and regulates the expression of extracel-
lular matrix proteins like fibronectin. This could be a first hint
that the activation of cGKI might have compensative effects
under high glucose conditions.
To gain a more detailed insight into the cellular processes under
high glucose conditions, we are using a proteomic approach with
LC/MS. With this tool, we are able to identify and quantify over
2000 proteins in one cell lysate sample and to compare the
proteome from differently treated cells.
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Background:
Soluble guanylate cyclase (sGC), the nitric oxide (NO) receptor,
has been a target for treating cardiovascular disease for over 150
years. sGC stimulators synergize with NO and show clinical prom-
ise, but the molecular binding site and the mechanism of action
have not been fully characterized. In the present study, a photo-
activatable sGC stimulator was coupled with LC-MS/MS and two-
dimensional NMR spectroscopy approaches were used to discover
a conserved sGC stimulator binding pocket.
Materials and Methods:
sGC stimulator IWP-854 containing a photolyzable diazirine and
PEG-linked biotin affinity tag was synthesized. Photoaffinity cross-
linking studies were conducted in human and Manduca sexta
(Ms) sGC, as well as in bacterial H-NOX homologs from Clostrid-
ium botulinum (Cb) and Shewanella woodyi (Sw). Cross-linkedproteins were digested using trypsin and analysed by nano-LC-
MS/MS. Additionally, protein transferred nuclear Overhauser effect
spectroscopy (Tr-NOESY) and chemical perturbation in heteronuc-
lear single quantum coherence (HSQC) NMR approaches were ap-
plied to various constructs of Ms sGC and bacterial H-NOX
homologs.
Results:
IWP-854 cross-linked to the β1 heme domain of human and Ms
sGC as well as to bacterial H-NOX homologs from Cb and Sw.
Competition of IWP-854 with BAY 41-2272 and IWP-051 (the par-
ent chemical core of IWP-854) in 1-, 5- and 50-fold molar excess
decreased the cross-linked protein in a concentration dependent
manner, suggesting that they bind to the same site. Cross-linked
peptides were identified using mass spectrometry and a novel
signature peak at 270.127 m/z and were exclusively localized to
the β1 heme domain and coiled-coil domain of purified human
sGC. The observation of NOE peaks derived from binding of IWP-
051 to Ms sGC and bacterial H-NOX homologs using Tr-NOESY
NMR recapitulated the cross-linking data. Additionally, several res-
idues displayed prominent concentration-dependent shifts in res-
onance upon titration with IWP-051 using well-characterized
HSQC spectra of Sw H-NOX. A computational model of stimulator
binding to the sGC heme domain was generated based on
current experimental data, available x-ray structures of domains
and previous chemical cross-linking studies1.
Conclusion:
These data suggest stimulators bind to a cleft between two sub-
domains in the sGC β1 heme domain, near a previously identified
tunnel of possible importance for NO escape from the heme
pocket2. Identifying the sGC stimulator binding pocket resolves a
long-standing question and may provide a path forward for
structure-guided drug discovery.
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Background:
PKG Iα is a central regulator of smooth muscle tone and nocicep-
tion and has been targeted for treating arterial and pulmonary
hypertension and chronic pain[1-4]. In particular, activating PKG
Fig. 5 (Abstract A45). The crystal structure of the PKG I C:N46
complex explains high selectivity of N46 for PKG Iα. ADP to ATP
conversion curves in the presence of N46 are shown for both PKG I
C and PKA Cα on the top and the crystal structure of the PKG I C
domain bound with N46 on the bottom. The structure of the PKG I
C:N46 complex is shown in a surface representation. The zoomed-in
view highlights N46 bound within the extended pocket formed be-
tween the small and large lobes. The surface is colored according to
the contact electrostatic potential calculated with APBS [9]. Positively
charged areas are shown in blue and negatively charged areas are
in red. Each data points were measured in duplicate using Kinase-
Glo Luminescent Assay. Error bars denote SEM
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that causes chronic pain in diseases such as nerve inflammation,
ischemia, and metastatic bone cancer[5-7]. A recent study
showed that a balanol like compound, N46, inhibits PKG Iα with
high potency and selectivity (Fig. 5) and attenuates thermal
hyperalgelia and osteoarthritic pain in rats[8]. However, little is
known about the molecular details of PKG Iα and N46
interaction.
Results:
To understand the molecular basis of high potency and selectiv-
ity of N46, we measured its inhibition constants for PKG Iα cata-
lytic (C) domain and determined their co-crystal structure at 2.5
Å resolution. Our measurements using Kinase-Glo Luminescent
Assay show that N46 inhibits PKG Iα C with an IC50 value of 3.7
nM (using BPDEtide as a substrate) while it inhibits PKA Cα with
360 nM (using Kemptide).
The crystal structure of PKG Iα C:N46 complex reveals that N46
binds to an elongated pocket that extends from the inner edge
to the outer rim of the active site of the active site within the C-
domain. In particular, N46 interacts with Gly348 at the glycine
rich loop and bulky residues at the inner surface of the αB helix
mainly through nonpolar interactions. Our structural model of the
cAMP dependent protein kinase (PKA) Cα docked with N46 shows
that a serine residue (Ser53) replaces Gly348 in the glycine rich
loop and may cause steric hindrance thus reducing interaction.
The model also shows that the same region at the αB helix in
PKA Cα has less bulky residues making no contact with N46.
Conclusion:
Our activation data show that N46 inhibits PKG Iα C with high af-
finity and selectivity over PKA Cα. Our co-crystal structure of the
PKG Iα C and N46 explains high potency and selectivity of N46
for PKG Iα and provides a starting point for structure guided design
of PKG I selective inhibitors.
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As a central part of the NO/cGMP signaling pathway soluble
guanylate cyclase (sGC) has become a promising therapeutic tar-
get in the treatment of cardiovascular diseases [1] and is thus
subject of intensive research. In the course of studies on bioacti-
vation of the anti-anginal drug nitroglycerin in blood vessels we
performed co-incubation experiments of purified sGC from bo-
vine lung with cytosols from porcine coronary arteries. Cytosolic
preparations considerably diminished NO-stimulated sGC activity
(Fig. 6a). This effect persisted in the presence of the phospodies-
terase inhibitor isobutylmethylxanthine, a protease inhibitor
cocktail, and superoxide dismutase, excluding cGMP hydrolysis,
proteolysis of sGC, and NO inactivation by superoxide as culprits.
Spectroscopic analysis of cytosols revealed the presence a
heme-containing protein with characteristic Soret and α/β bands
(Fig. 6b). Using Western blot and LC-MS/MS analysis we identi-
fied the protein as hemoglobin, which is known to effectively
scavenge NO [2]. Heme-mediated NO scavenging by cytosolic
preparations was confirmed with an NO-sensitive electrode (Fig.
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 23 of 356c). Removal of hemoglobin by haptoglobin affinity chromatog-
raphy revealed an unexpected increase of NO-stimulated sGC ac-
tivity by cytosols (Fig. 6d). The effect was dependent on the
amount of cytosolic protein added (Fig. 6e), precipitable by am-
monium sulfate (Fig. 6f), and sensitive to heat and organic sol-
vents. Preliminary results indicate that this protein, termed sGC-
activating factor (sGC-AF) can be recovered by gel filtration.
Work on isolation and identification of sGC-AF is ongoing in our
laboratory. Our findings demonstrate expression of an as yet un-
identified protein in porcine coronary arteries that activates sGC,
resulting in increased vmax of the maximally NO-stimulated
enzyme.
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154:99-136.Fig. 6 (Abstract A46). NO-scavenging and sGC-activating properties of
PCA cytosols. a Protein-dependent reduction of NO-stimulated cGMP
formation in the presence of cytosols b) UV/Vis spectra of cytosols under
various conditions c) Correlation of NO consumption and heme content
of cytosols d) Effect of native or hemoglobin-depleted cytosols on
NO-stimulated cGMP formation e) Protein-dependent increase of NO-
stimulated cGMP formation in the presence of hemoglobin-depleted
cytosols f) Selective precipitation of the activating factor by ammonium
sulfate, * p<0.05A47
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Clinical background:
Several reports indicate cancer stem cells (CSCs) may act a central
role in pancreatic ductal adenocarcinoma (PDAC) metastasis and re-
currence. However, no clinical available approach is established.
cGMP is known as a second messenger plays a crucial role in penile
erection and vascular homeostasis. We previously reported that
cGMP acts the signal mediator in 67-kDa laminin receptor-dependent
multiple myeloma cell death1. Here we show cGMP induction drastic-
ally suppressed CSC properties in three different PDAC cell lines in-
cluding Panc-1, Miapaca-2 and BxPC-3 cells. Our microarray analysis
showed cGMP-induction suppressed FOXO3 (see Fig. 7a). We also
showed FOXO3 are strongly expressed in CD44+ cells2. Surprisingly,
FOXO3, known as the tumour suppressor plays the crucial role in the
maintenance of CSC properties and FOXO3 knock down strongly
suppressed CSC properties by downregulation of CD44, the essential
protein for CSC properties (see Fig. 7b, c). The same results were ob-
tained in vivo2.
Conclusion:
Considering the FOXO3 knock out mice did not change survival period,
cGMP induction and FOXO3 suppression could be the novel strategies
for PDAC therapy.
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stem cell properties. a cGMP induction suppressed FOXO3. b Silencing
of FOXO3 suppressed CSC properties. c cGMP induction suppresses
pancreatic cancer stem cell properties
Fig. 8 (Abstract A48). GTN-induced NO formation and cGMP
accumulation in intact cells. a. NO release over time was measured
in VSMC infected with C-geNOp alone or in combination with either
WT or C301S/C303S ALDH2 in response to 1 μM GTN b. Representative
curves showing NO release in response to cumulative increasing GTN
concentrations (10 nM – 1 μM) in VSMC expressing C301S/C303S
ALDH2 c. Effect of 0.2 mM daidzin on GTN-derived NO formation
d. GTN-induced cGMP accumulation in non-infected and infected
(WT or C301S/C303S ALDH2) porcine aortic endothelial cells
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Aldehyde dehydrogenase-2 (ALDH2) catalyzes vascular
bioactivation of the antianginal drug nitroglycerin (GTN),
resulting in 3´,5´-cyclic guanosine monophosphate (cGMP)-me-
diated vasodilation through activation of soluble guanylate cy-
clase (sGC). We have previously shown that a minor reaction
of ALDH2-catalyzed GTN bioconversion, accounting for about
5% of the main clearance-based turnover yielding inorganic ni-
trite, results in direct nitric oxide (NO) formation and con-
cluded that this minor pathway could provide the link
between vascular GTN metabolism and activation of sGC [1].
However, the biological significance of NO formation by puri-
fied ALDH2 is questioned by the persistent failure to detect
release of NO in vascular tissue and cells exposed to thera-
peutically relevant GTN concentrations (<1 μM). To address
this issue, we took advantage of a novel, highly sensitive gen-
etically encoded fluorescent NO probe (C-geNOp) that enables
real-time monitoring of intracellular NO formation in cultured
vascular smooth muscle cells (VSMC) expressing either wild-
type ALDH2 or a mutant (C301S/C303S ALDH2) that reduces
GTN to NO but lacks clearance-based GTN denitration activity.
Addition of 1 μM GTN to VSMC expressing either wild-type or
C301S/C303S ALDH2 resulted in a pronounced increase in
intracellular NO, with maximal concentrations of 7 and 17 nM,
respectively (Fig. 8a). In VSMC expressing C301S/C303S ALDH2
NO formation was detectable at therapeutically relevant sub-
micromolar concentrations (10 nM – 1 μM) of the nitrate (Fig.
8b). The selective ALDH2 inhibitor daidzin (0.2 mM) completely
inhibited GTN-derived NO formation in a rapid and reversible
manner (Fig. 8c). Formation of GTN-derived NO correlated well
with activation of purified sGC in VSMC lysates as well as
cGMP accumulation in cultured porcine aortic endothelial cells
that had been infected with wild-type or C301S/C303S ALDH2
(Fig. 8d). Our findings demonstrate that ALDH2-catalyzed NO
formation is necessary and sufficient for vascular bioactivation
of GTN.
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Diastolic heart failure, often referred to as HFpEF (heart failure
with preserved ejection fraction) accounts for about 50% of heart
failure cases. Currently, there is no good treatment for this condi-
tion. Changes associated with HFpEF are impaired left ventricular
(LV) filling, increased LV stiffness and altered expression and
phosphorylation of the elastic sarcomeric protein titin. The main
function of titin is to keep the structural integrity of the sarco-
mere intact, but also function as an elastic spring, contributing to
passive tension development within the myocytes. Protein kinase
G (PKG) has earlier been shown to phosphorylate titin and de-
crease passive stiffness in human myofibrils, thus allowing more
compliant cardiomyocytes. PKG can be activated by cGMP in-
creased either by nitric oxide (NO) through the activation of sol-
uble guanylyl cyclase (sGC) or by the natriuretic peptides (NPs)
through the activation of the particulate guanylyl cyclases NPR-A
(GC-A) or NPR-B (GC-B). The aim of this study was to determine
which receptor-mediated signaling pathways induce PKG-
dependent titin phosphorylation and reduce passive force devel-
opment. Cyclic GMP levels, titin phosphorylation, phosphomap-
ping of the titin protein and passive tension were performed in
isolated rat cardiomyocytes. C-type NP (CNP), stimulating NPR-B,
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 25 of 35brain NP (BNP) stimulating NPR-A and SNAP (NO donor) stimulat-
ing sGC all increased cGMP. However, only CNP increased titin
phosphorylation and decreased passive tension in single cardio-
myocytes. Thus, despite increasing cGMP, activating NPR-A or sGC
did not reduce cardiomyocyte stiffness, whereas NPR-B activation
did. This indicates compartmentation of the different signaling
pathways increasing cGMP. Further, our results suggest NPR-B as
a potential target to improve LV filling by decreasing LV stiffness
in HFpEF patients.
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Clinical background:
Drugging cancer metastases, extremely deadly diseases, has been
on high demand but still challenging. Metastasis is a step-wise
complex phenomenon including dynamic physiological alterna-
tions of both cancers and host. Cancers set up a favorable envir-
onment (soil) in distant organs for disseminated cancer cells
(seeds) to efficiently metastasize: pre-metastatic niche hypothesis.
Pre-metastatic niche is a possible target for targeting metastasis.
We have previously reported that atrial natriuretic peptide (ANP),
an endogenous peptide produced by the heart, inhibits
hematogenous cancer metastasis through vascular endothelial
cells. We showed that ANP inhibits the tumor cell adhesion to
the vascular endothelium by suppressing E-selectin expression,
which has a central role in the adhesion of tumor cells to endo-
thelial cells. In this study, we show that ANP suppresses pre-
metastatic niche formation and following metastasis when
pharmacologically supplied in tumor-bearing mice. ANP adminis-
tration reduced the lung metastasis in the mouse models of 4T1
breast cancer and colon26 cancer. Comprehensive RNA-seq ana-
lyses using the 4T1 and Lewis Lung Carcinoma (LLC) models
demonstrated that gene expression changes characteristics of
pre-metastatic niche in the lung were suppressed by ANP treat-
ment. The lung of mice overexpressing GC-A, a receptor for ANP,
in endothelial cells, was resistant to pre-metastatic niche forma-
tion than the WT lung. Neither ANP administration nor GC-A
overexpression had a hazardous effect on the lung gene expres-
sions in a cancer-free condition. In summary, we showed that the
endothelial ANP-GC-A signaling attenuates pre-metastatic niche
formation in the lung in a context-specific manner.
Conclusion:
Altogether, we concluded that ANP-GC-A signaling as a promising
target for controlling hematogenous cancer metastasis and pre-
metastatic niche formation in various types of cancers.A51
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Axonal branching is essential for correct formation of neuronal networks
and subsequent transmission of information throughout the body. It is
well known that a cGMP signaling cascade consisting of C-type natri-
uretic peptide (CNP), guanylate cyclase B (GC-B, also known as Npr2)
and cGMP-dependent protein kinase I (cGKI) is crucial for axon bifur-
cation of dorsal root ganglia (DRG) sensory neurons and cranial sensory
ganglia neurons during mouse embryonic development. In this study,
we investigated (1) whether other components of the cGMP signaling
pathway, namely phosphodiesterases (PDEs) and the natriuretic peptide
“clearance” receptor Npr3, are also involved in the bifurcation of embry-
onic DRG neurons and (2) whether CNP-evoked increase of cGMP regu-
lates the intracellular Ca2+ level in DRG neurons. RT-PCR screens, in situ
hybridization, and fluorescence resonance energy transfer-based live-cell
cGMP imaging revealed PDE2A as the major enzyme responsible for the
degradation of CNP-induced cGMP in embryonic DRG neurons. Interest-
ingly, cGMP measurements and DiI labeling of PDE2A knockout embryos
indicated that an elevated cGMP level does not disturb axon bifurcation
of DRG neurons. Npr3 is expressed in cells of the roof and floor plate of
the spinal cord as well as in the dorsal roots of E12.5 mouse embryos.
Npr3 likely acts as a clearance receptor for CNP and might, therefore,
lower the activity of the CNP/GC-B/cGMP cascade in DRGs. In the ab-
sence of Npr3, and presumably higher cGMP levels in DRG neurons, a
small proportion of sensory axons showed deficits in bifurcation by turn-
ing either in rostral or caudal direction, while most axons branched nor-
mally. Fura-2-based Ca2+ imaging revealed that acetylcholine (ACh) and
ATP induce Ca2+ transients in somata and growth cones of E12.5 DRG
neurons, respectively. Simultaneous imaging of cGMP and Ca2+ signals
showed that the ACh/ATP-induced Ca2+ transients were strongly sup-
pressed by CNP-induced cGMP. The suppressive effect of cGMP on
agonist-induced Ca2+ signals was absent in DRG neurons of cGKI knock-
out mice demonstrating that the cGMP/Ca2+ crosstalk is mediated by
cGKI. Altogether, our study indicates that DRG sensory axon bifurcation
tolerates increased cGMP levels in PDE2A or Npr3 knockout mice. Fur-
thermore, we discovered a crosstalk between cGMP and Ca2+ signaling
in embryonic DRG neurons that might provide a mechanistic basis for
axon bifurcation.
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Soluble guanylate cyclase (sGC) is an enzyme involved in signal
transduction which catalyzes the formation of cGMP from GTP
and is activated by the binding of NO to its heme group. The
NO – cGMP – sGC signaling pathway participates in a wide range
of regulating processes for intracellular metabolism: regulation of
blood pressure through smooth muscle relaxation and vasodila-
tion, apoptosis, signaling in tumor cell proliferation, angiogenesis,
immune response and inflammation. This study was aimed at dis-
covering sGC inhibitors and to understand their binding
mechanism.
The effect of 200 natural compounds from a chemical library, in-
cluding hypericin and hypocrellin (two potential agents for
photodynamic therapy), have been investigated on sGC activity.
Subsequently, hypericin, hypocrellin and four other natural com-
pounds from plants and fungi: stictic acid, violastyrene, 2-
hydroxy-3,5,8-triaceto-1,4-naphthoquinone (HTANQ), 3,6-dibromo-
purpurogallin (DBPG) were shown to inhibit sGC in vitro and in
HUVEC cells.
Using immunoenzymatic assay of sGC activity, we measured the
cross effects of these inhibitors with NO and with the activator BAY
41-2272.
The inhibition constant (Ki) for cGMP synthesis (Fig. 9) measured
in vitro on purified sGC (hypericin: 0.3 μM; hypocrellin: 0.6 μM,
stictic acid: 0.2 μM, violastyrene: 0.8 μM, HTANQ: 0.2 μM, DPG:
0.7 μM) was lower than that measured in vivo on HUVEC (hyperi-
cin: 0.7 μM; hypocrellin: 1.5 μM, stictic acid: 43 μM, violastyrene:
14 μM, HTANQ: 28 μM). We noted that DBPG does not pass
through the HUVEC cell membrane.
In vitro, the presence of the NO-independent activator BAY 41-
2272 bound to sGC does not change the inhibition induced by
these compounds. In vivo, BAY 41-2272 reduces the hypericin/
hypocrellin induced inhibition of sGC but does not influence the
inhibition constant of compounds from plants and fungi.
By surface plasmon resonance, we showed irreversible binding of hy-
pericin, hypocrellin and DBPG to guanylate cyclase in comparison
with other studied inhibitors.
Conclusion:
Our results demonstrate that the discovered inhibitors are allo-
steric modulators which bind neither to the heme, nor to the
catalytic and activator sites, revealing a new class of pharmaco-
logical compounds for sGC.
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Fig. 9 (Abstract A52). Inhibition of purified sGC (solid curves) and
sGC in HUVEC cells (dotted curves) by the natural compounds.
Density of cells was 5.6 × 105 cells/ml. Activity was measured as
synthesized cGMP in the presence of the NO-donor nitroprusside
(300 μM)A53
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Both activating mutations in fibroblast growth factor receptor 3 (FGFR3)
and inactivating mutations of guanylyl cyclase B (GC-B), also called NPRB
or NPR2, cause human dwarfism. Reciprocal regulation of the two path-
ways has been reported, but how FGFR3 inhibits GC-B is not known.
Here, we demonstrate that FGF2 stimulation of FGFR3 causes a rapid, po-
tent, and reversible inhibition of endogenous GC-B enzymatic activity in
rat chondrosarcoma cells. FGF2 concomitantly reduced the phosphate
content and enzymatic activity of GC-B, and the serine and threonine
phosphatase inhibitor, cantharidin, blocked the FGF2-dependent reduc-
tion in the enzymatic activity of GC-B. A mutated form of GC-B containing
glutamate substitutions for all confirmed and putative phosphorylation
sites, such that it cannot be inactivated by dephosphorylation, was not
inactivated by FGF2. We conclude that FGF2 activation of FGFR3 inacti-
vates GC-B by a reversible dephosphorylation mechanism and suggest
that dephosphorylation is a universal inactivation mechanism commonly
employed by natriuretic peptide-stimulated guanylyl cyclase receptors.
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Activating and inactivating mutations in guanylyl cyclase (GC)-B cause
skeletal overgrowth and dwarfism, respectively. C-type natriuretic peptide
(CNP) dependent stimulation of GC-B requires receptor phosphorylation
on multiple residues. A knock-in mouse expressing a mutant GC-B where
all known phosphorylation sites were mutated to glutamate to mimic a
constitutively phosphorylated enzyme, called GC-B7E/7E, was created that
has a longer appendicular skeleton. Here, we show that GC-B7E/7E mice
have 30% more trabecular bone volume and number, 10% greater cor-
tical bone thickness and area, and 20% more bone mineral density at 9
weeks compared to GC-BWT/WT mice. 3-point bending assays demon-
strated that 9 week bones from GC-B7E/7E mice have 35% increased
strength and stiffness and 65% increased toughness compared to wild-
type mice, all of which can be attributed to the increased cortical bone.
At 16 weeks, cortical area and bone mineral density are still 14% and
22% greater in GC-B7E/7E mice. However, no difference in trabecular bone
volume and number was observed between the two mouse lines at 16
weeks, due to GC-B7E/7E trabecular bone loss. Why the trabecular bone in-
creases observed at 9 weeks are absent at 16 weeks is not known. These
data indicate that blocking GC-B dephosphorylation and inactivation in-
creases cortical and trabecular content, density, stiffness, and strength of
long bones at 9 weeks. At 16 weeks the cortical gains are diminished
and the trabecular gains are lost. We suggest that therapeutics that in-
crease GC-B phosphorylation may decrease fracture healing time and/or
prevent post-menopausal osteoporotic bone loss.
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Introduction:
Treatment with sGC stimulators or activators has resulted in kidney pro-
tection in a variety of preclinical animal models. A key surrogate for effi-
cacy in treating chronic kidney disease progression is albuminuria.
Currently, common kidney in vivo models with albuminuria as primary
endpoint are chronic models, with duration of up to several months. This
is a significant hurdle in the search for novel kidney protective agents like
sGC modulators.
Methods:
We developed a new, short-term model that will enable us to study
novel drugs with the potential ability to reduce albuminuria. Urine was
collected for four hours from wildtype C57/Bl6J mice that had received
two simultaneous injections of angiotensin II (AngII, 10 μg i.v. + 10 μg
s.c.). Albuminuria was measured as albumin-creatinine ration (ACR) with
Roche Cobas I400. Group sizes ranged from 5-9 mice. All treatments
were given orally prior to AngII. Data are reported as means +/- SD.
Results:
Application of AngII resulted in a robust and significant albuminuria (mean
ACR 123 μg/mg vs. 13 μg/mg in control mice). No albuminuria was detect-
able 24h after AngII application. We investigated the sGC stimulator BAY
41-2272 and the sGC activator BAY 60-2770 in this model. Both com-
pounds had demonstrated significant anti-proteinuric effects in different
long-term studies (data not shown). Treatment with 3 mg/kg BAY 60-2770
reduced albuminuria by 71% compared with the control group (Fig. 10a).
In a second experiment, the sGC stimulator BAY 41-2272 reduced albumin-
uria significantly by 54% and 62% at 1 and 3 mg/kg respectively (Fig. 10b).
Losartan was used in both studies as positive control.
Conclusion:
Our new mouse model was capable of demonstrating albuminuria-
reducing effects of select sGC modulators within a few hours experi-
mental setting. We propose the use of this model as robust and fast
platform for the screening of novel drugs in albuminuric diseases.
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Albuminuria was significantly increased within 4h after AngII bolus
injections. The albuminuria ratio was significantly reduced in the
experimental group treated with sGC activator BAY-602770 to a mean
35±26 μg/mg at the dose 3 mg/kg (a). Treatment with the sGC
stimulator BAY 41-2272 significantly reduced the albuminuria to
a mean 50± 49 μg/mg and 42± 35 μg/mg in the respective
doses of 1 and 3mg/kg (b). Losartan treated animals showed a highly
significant reduction of AngII induced albuminuria by around 90%, N.D
= not detectable albuminuria, Data are mean ± SD */**/***/****=
significant with p<0.05/0.01/0.001/0.0001 vs. AngII (One-way ANOVA
followed by Dunnett´s Multiple Comparison post-hoc analysis)A56
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Clinical background:
In contrast to the previous scientific views, recent studies have indi-
cated that pressure overload-induced left ventricular myocardial hyper-
trophy (LVH) is pathological in principal. Therefore in the last decades,
understanding the molecular basis of LVH in order to prevent its mani-
festation has been the focus of interest. As a result, the soluble guany-
late cyclase (sGC) - cyclic guanosine monophosphate (cGMP) – protein
kinase G pathway has been identified as a potent anti-hypertrophic sig-
naling, which may offer possibilities for pharmaceutical interventions.
Purpose:
In the present study the novel sGC activator Cinaciguat was tested in
a rodent model of pressure overload-induced LVH.
Methods:
Constriction of the abdominal aorta at the suprarenal level (aortic banding;
AB) was performed to establish hypertension in the proximal part of the
aorta for 6 or 12 weeks. Sham operated animals were used as controls.
From the 7th to the 12th experimental week 10mg/kg/day cinaciguat
(Cin) or placebo (Co) was administered p.o. Serial echocardiography and
invasive pressure-volume analysis were carried out to assess the morpho-
logical and functional alterations of the left ventricle. Furthermore, histo-
logical and molecular biological measurements were performed.
Results:
Activation of the sGC enzyme by cinaciguat effectively reduced the
hypertrophic remodeling of the myocardium as evidenced by de-
creased heart weight-to-tibial length ratio (0.57±0.02 vs. 0.48±0.02g/
cm, p<0.05 AB 12th week-Co week vs. AB 12th week-Cin), decreased
cardiomyocyte diameter (23.94±0.59 vs. 20.02±0.20μm, p<0.05 AB 12th
week-Co week vs. AB 12th week-Cin) and reduced myocardial expres-
sion levels of atrial natriuretic peptide and β/α-myosin heavy chain ra-
tio. In addition, the cinaciguat treatment also inhibited the increased
collagen accumulation in the interstitium (Masson’s score: 1.7±0.2 vs.
1.2±0.1, P<0.05 AB 12week-Co vs. AB 12week-Cin) and provided protec-
tion against the nitro-oxidative stress. All of these beneficial structural
and molecular alterations manifested in significantly improved cardiac
function (ejection fraction: 47.4±2.7 vs. 63.7±2.4%, P<0.05 AB 12week-
Co vs. AB 12week-Cin).
Conclusion:
Here we provided evidence, that chronic activation of the sGC en-
zyme might represent a novel therapy in case of pressure overload-
induced LVH and cardiac dysfunction.
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Cyclic GMP (cGMP) is a central second messenger, regulating a multi-
tude of cellular and physiological processes, like the visual cascade,
electrolyte homeostasis, and smooth muscle relaxation (Lucas et al.,
2000). Recently, a rhodopsin-guanylyl cyclase (RhGC) from the
aquatic fungus Blastocladiella Emersonii was characterized (Scheib
et al., 2015, Gao et al., 2015), which produces cGMP upon a short
flash of green light and can be expressed in different mammalian cell
types (Fig. 11). Due to the direct linkage between the rhodopsin and
the cyclase domain, RhGC represents the first member of a novel
class of enzyme linked rhodopsin (2). Here, we further characterize
RhGC of Blastocladiella Emersonii (BE) enzymatically and with the help
of X-ray crystallography. Additionally, we found an orthologue vari-
ant, RhGC from Catenaria Anguillulae with improved photo-stability,
which can also be functionally expressed in different eukaryotic cell
types. Like for the BE version, the onset of cGMP production was
rapid and cGMP signals could be induced repeatedly, while no dark
activity was apparent.
Conclusion:
Rhodopsin-guanylyl cyclases are a versatile optogenetic tool to
analyze cGMP-dependent signaling processes in cell biology and the
neurosciences.
Conflict of interest
The authors declare that they do not have a potentially perceived
conflict of interest.
References:
Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., …
Waldman, S. A. (2000). Guanylyl cyclases and signaling by cyclic GMP.
Pharmacological Reviews, 52(3), 375–414. Retrieved from http://
www.ncbi.nlm.nih.gov/pubmed/10977868
Scheib, U., Stehfest, K., Gee, C. E., Körschen, H. G., Fudim, R., Oertner, T. G., &
Hegemann, P. (2015). The rhodopsin-guanylyl cyclase of the aquatic
fungus Blastocladiella emersonii enables fast optical control of cGMP
signaling. Science Signaling, 8(389), rs8. doi:10.1126/scisignal.aab0611
Gao, S., Nagpal, J., Schneider, M. W., Kozjak-Pavlovic, V., Nagel, G., &
Gottschalk, A. (2015). Optogenetic manipulation of cGMP in cells and
animals by the tightly light-regulated guanylyl-cyclase opsin CyclOp.
Nature Communications, 6, 8046. doi:10.1038/ncomms9046GTP
cGMP +PPi
Fig. 11 (Abstract A57). Model of the Rhodopsin-guanylyl cyclase.
Activation with green light (500 ms) leads to the production of cGMPA58
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cGMP signalling activated by C-type natriuretic peptide (CNP) and its
receptor, the particulate guanylate cyclase B (GC-B, also known as
Npr2), is critically involved in the regulation of endochondral ossifica-
tion, the maturation of oocytes and the homeostasis of arterial blood
pressure. Biallelic loss-of-function mutations in the human NPR2 gene
result in acromesomelic dysplasia type Maroteaux (AMDM), a skeletal
dysplasia with an extremely short and disproportionate stature. Simi-
lar to human patients, constitutive GC-B-deficient mice are character-
ized by a dwarfed phenotype. Adding to the physiological functions
of the CNP/GC-B-system, our studies revealed that CNP/GC-B-induced
cGMP signalling via cGMP-dependent protein kinase I controls bifur-
cation of sensory axons in the embryonic spinal cord or brain stem.
In the absence of any one of these components the axons of neu-
rons from the dorsal root ganglia or cranial sensory ganglia no lon-
ger bifurcate and instead turn either in an ascending or descending
direction.
GC-B forms a homodimeric transmembrane receptor composed of
an amino-terminal extracellular ligand-binding-domain, a single
membrane-spanning region, and an intracellular kinase homology
domain (KHD) followed by a dimerization segment and a
carboxyl-terminal guanylate cyclase domain. Previous studies re-
ported that phosphorylation of seven regulatory serine and threo-
nine residues in the KHD of GC-B is a prerequisite for ligand-
induced cGMP formation. However, whether phosphorylation of
these sites in GC-B is also required in physiological systems
needs to be confirmed.
To address this question we applied CRISPR/Cas9 genome editing
to generate a knock-in mouse mutant in which each site was
substituted by alanine (GC-B-7A), resulting in a nonphosphorylata-
ble enzyme. Biochemical analysis of guanylate cyclase activity in
tissues from GC-B7A/7A mice demonstrated a significant reduction
in cGMP levels generated upon stimulation by CNP. Interestingly,
we also detected a decrease in guanylate cyclase activity in the
heterozygous GC-BWT/7A mice as compared to wild type mice
which might be due to a dominant negative effect of the mutant
form of the receptor. GC-B7A/7A mice exhibit a dwarfed pheno-
type as well as a lack of sensory axon bifurcation, thereby mim-
icking observations from global GC-B knock-out mice. In contrast,
no alterations in axon bifurcation were found in a glutamate-
substituted mouse mutant of GC-B (GC-B-7E) that cannot be inac-
tivated by dephosphorylation.
In conclusion our studies demonstrated that phosphorylation of
regulatory serine and threonine residues in the KHD is required for
activation of cGMP generation by GC-B and physiological function
such as bone growth and axon bifurcation.
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Introduction:
Cardiomyocyte β3-adrenoceptor (β3-AR) levels are increased in car-
diac diseases where they alleviate pathological hypertrophy and cel-
lular remodelling through 3’,5’-cyclic guanosine monophosphate
(cGMP) signalling [1].. However, the subcellular compartmentation of
β3-AR/cGMP signaling, its regulation by phosphodiesterases (PDEs)
and its alterations in heart failure require further investigation.
Objective:
To directly visualize β3-AR/cGMP signaling, study receptor localization
and β3-AR microdomain regulation by PDEs as well as receptor inter-
action partners in healthy and failing cardiomyocytes.
Methods and Results:
Adult rat ventricular cardiomyocytes expressing the cGMP-specific
Förster Resonance Energy Transfer (FRET) biosensor red cGES-DE5
were stimulated with the β-AR agonist isoprenaline. This led to the
generation of cGMP in a β3-AR/NO/soluble guanylyl cyclase (sGC)-
dependent manner. The PDEs 2 and 5 proved to be the main de-
graders of β3-AR/cGMP as determined by selective, pharmacological
inhibition of cGMP PDEs. FRET in combination with scanning ion con-
ductance microscopy revealed a shift of functional β3-ARs from the
T-tubules of healthy cardiomyocytes to unstructured membrane
areas of cardiomyocytes in heart failure. This shift was also inducible
in healthy cells by disrupting the scaffolding domain of Caveolin 3
(C3SD) with the TAT-C3SD peptide. In heart failure, significantly lower
β3-AR-stimulated cGMP levels and increased PDE2 activity were de-
tected. Immunocytochemical staining also revealed reduced sGC as-
sociation with caveolin-rich membrane fractions in failing cells.
Conclusions:
In healthy cardiomyocytes functional β3-ARs are localized in T-
tubules and β3-AR/cGMP levels are regulated by PDE2 and PDE5.
Heart failure leads to redistribution of functional β3-ARs and sGC
from T-tubules to detubulated membrane areas. Together with in-
creased PDE2 activity, this can disrupt receptor-associated cGMP mi-
crodomains and impair potentially protective β3-AR/cGMP signaling.
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Activation of soluble guanylyl gyclase (sGC) is regarded as an in-
novative therapeutic concept for the treatment of various path-
ologies associated with oxidative stress including pulmonary
hypertension and acute heart failure. Belonging to the group of
so-called sGC activators, cinaciguat (BAY 58-2667) and BAY 60-
2770 are supposed to preferentially stimulate either oxidized (fer-
ric) or heme-depleted (apo) sGC [1]. This concept has been chal-
lenged by studies demonstrating complete relaxation of intact
uninjured blood vessels exposed to these drugs [2]. To investi-
gate this apparent discrepancy, the effect of cinaciguat on relax-
ation of micro- and macrovessels was tested and compared to
tissue cGMP levels. Moreover, using purified sGC from bovine
lung the mechanism of enzyme activation by cinaciguat was
studied in greater detail. Organ bath experiments showed that
the drug caused time-dependent relaxation of precontracted cor-
onary vessels (See Fig. 12). The dilatory response was not af-
fected by extensive washout over a period of 1 hour indicating
virtually irreversible relaxation. Cinaciguat-induced relaxation was
associated with a time- and concentration-dependent increase in
vascular cGMP measured by radioimmuno assay. Washout of the
drug for 1 hour had no effect on vascular cGMP levels. The irre-
versible type of action was also observed in experiments with
cultured porcine aortic endothelial cells.
Activation of purified sGC by cinaciguat resulted in moderate
cGMP formation i.e. ~10% of maximal activity induced by the
NO donor sodium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-dio-
late (DEA/NO). Oxidation of the enzyme with 1H-[1,2,4] oxadia-
zolo[4,3-a]quinoxalin-1-one (ODQ) to its ferric state did not
significantly increase cinaciguat-induced sGC activity. The de-
gree of ferric enzyme activation was neither affected by con-
centration (1-100 nM of cinaciguat) nor incubation time (10-90
min). By contrast, heme-depleted sGC was activated by cinaci-
guat in a concentration-dependent manner yielding values com-
parable or higher than measured in the presence of a
maximally active concentration of the NO donor. According to
the results obtained with isolated vessels cinaciguat-induced
sGC activation was irreversible (at least for 90 min).
Conclusion:
Cinaciguat induced irreversible relaxation of intact uninjured cor-
onary arteries and aortas. The irreversible mode of action was
also observed in experiments with cultured porcine endothelial
cells and purified bovine lung sGC. Assuming that under physio-
logical conditions cells contain a small pool of sGC as heme-free
species our data indicate that cinaciguat is capable of continu-
ously shifting the cellular equilibrium between NO-sensitive sGC
and heme-free apo sGC towards latter population. Hypotensive
side effects of cinaciguat therapy observed in clinical trials [3]
may substantiate this hypothesis.
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Fig. 12 (Abstract A60). Effect of cinaciguat on vasorelaxation.
Cinaciguat (1-100 nM) induced time-dependent relaxation of
K+-precontracted porcine coronary arteries a. The dilatory effect of
cinaciguat was not reversed upon extensive washout of the drug
for 1 hour b. Data represent mean values±SEM of 7 individual
experiments
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Background:
Aortic aneurysms and dissections account for 1-2% of all deaths in
the U.S.; aortic media degeneration is a hallmark of the disease, and
involves smooth muscle cell (SMC) dysfunction and elastin degrad-
ation. A heterozygous gain-of-function mutation (R177Q) in protein
kinase G 1 (PKG1) was recently identified as the cause of early-onset,
high-penetrance familial thoracic aortic aneurysms and dissections
[1]. Among many other physiological processes, PKG1 controls vascu-
lar contractility and keeps smooth muscle cells (SMCs) in a differenti-
ated, quiescent, and contractile state [2].
Results:
We generated mice carrying a R177Q (RQ) knock-in mutation, which
causes constitutive, cGMP-independent enzyme activation. At 8-12
months of age, heterozygous PKG1RQ/+ mice show aortic media degen-
eration with increased elastin fiber fragmentation and collagen accumu-
lation, decreased SMC count, and aortic dilatation. The aortic pathology
in younger PKG1RQ/+ mice is aggravated by hypertensive stress and re-
sults in increased mortality due to aortic rupture after transverse aortic
constriction surgery. Generation of reactive oxygen species (ROS) is in-
creased in aortic SMCs from PKG1RQ/+ mice, and there is evidence of
oxidative damage and altered contractile and ECM gene expression in
the aorta of PKG1RQ/+ mice compared to wild type litter mates.
Conclusion:
PKG1-R177Q increases ROS generation in aortic SMCs causing oxida-
tive damage in aortic media, altered contractile and ECM gene ex-
pression, and impaired aortic wall maintenance and repair.
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Background:
Pericytes are vascular cells which can be found in the basal mem-
brane (BM) around blood capillaries. They are closely related to vas-
cular smooth muscle cells (VSMC). However, pericytes can be
distinguished from VSMC through morphology and specific markers
such as platelet-derived growth factor receptor ß (PDGFR-ß) or des-
min. Recent data indicate that pericytes could be the main precursor
of myofibroblasts in the lung which deposit extracellular matrix in
the interstitium during lung fibrosis.
Methods:
Pericytes were isolated from mouse lung and seeded on collagen-coated
glass until they reached confluency of ~ 90%. For immunohistochemistry
(IHC), the cells were fixed, permeabilized with digitonin or Triton-X-100,
stained with specific antibodies and viewed under a confocal fluores-
cence microscope. Only primary pericytes cultures were used. To investi-
gate differentiation into myofibroblasts, lung pericytes were isolated,
seeded onto collagen-coated wells and stimulated with 10 ng/ml trans-
forming growth factor ß (TGF-ß) - a well-known fibrosis trigger in the
lung. After 72 h incubation, the cells were lysed and the protein content
of α smooth muscle actin (αSMA) and NO-GC was determined using
Western blot (WB). Histone H3 was used as housekeeping gene.
Results:
The isolated cells were confirmed as pericytes based on fact that
90% were immunopositive for PDGFR-ß and 60% were positive for
desmin. Moreover, pericytes from WT were positive for NO-GC in IHC
and WB; yet, with both methods, NO-GC was shown to be absent in
pericytes from global NO-GC knockout mice (GCKO). While αSMA ex-
pression was low in untreated pericytes (IHC and WB), TGF-ß strongly
increased the expression of αSMA. Interestingly, TGF-ß also led to an
increase in the NO-GC level in pericytes.
Discussion:
In summary, we established a protocol to isolate NO-GC-expressing
pericytes from mouse lung. These cells can differentiate into myofi-
broblasts upon treatment with the profibrotic TGF-ß. The identifica-
tion of pericytes as a precursor of myofibroblasts is an important
step in the treatment of lung fibrosis. Pericytes could be a target for
a therapy of lung fibrosis. NO-GC stimulators are known to have anti-
proliferative and/or apoptotic effects. Further studies are directed to
test the antifibrotic potential of NO-GC stimulation in vitro and
in vivo.
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BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 31 of 35Some of the diatomic diffusible molecules, like O2, CO and NO are
involve in vital biochemical processes and are classified among the
indispensable signaling molecules in all kingdoms of life. Heme-nitric
oxide/oxygen binding (H-NOX) domain is found either as a stand-
alone protein consisting of approximately 200 amino acids in length
or fused to other domains within larger proteins, such as in soluble
guanylate cyclase (sGC) and is conserved across eukaryotes and bac-
teria. sGC-related proteins consist if a heme-binding N-terminal do-
main (H-NOX) that regulates the catalytic site located in the C-
terminal end of the protein. sGC is an heterodimer, comprising by an
α1 or α2 subunit combined with β1 subunit catalyzing the conver-
sion of GTP to cGMP. Within sGC, the H-NOX domain in the β1 sub-
unit functions as a sensor for the diffusible signaling agent nitric
oxide (NO). In the vasculature, NO increases the activity of sGC by
several hundred fold, and results in vasodilation and inhibition of
platelet aggregation. Oxidative stress is the key-factor for heme loss
of sGC and consequently, the inability of NO activation. This condi-
tion leads the enzyme to degradation and as a result the NO signal-
ing pathway is disrupted. Several chemical compounds like
cinaciguat (BAY 58-2667), are heme-independent activators which
protects sGC from proteasomal degradation.
However, the critical determinants of the gas filtering and the coord-
ination to the iron(II) heme are still not completely elucidated. In the
present study we investigate the conformational and the electronic
properties of the HNOX domain from Nostoc sp. which exhibits 35%
sequence homology with the corresponding one from human sGC.
For the structural and dynamic characterization of the protein during
the Fe(II) oxidation state, we performed 2D and 3D homo- and het-
eronuclear NMR experiments in solution as well as UV-visible spec-
troscopy. Furthermore, we conducted experiments in order to
examine the changes upon the heme molecule after the interaction
with chemical compounds and oxidizing agents (NO, BAY 58-2667,
ODQ). The manner by which the oxidation status of Fe(II)-Protopor-
phyrin IX prosthetic group affect the structure and the dynamical be-
havior of HNOX domain will allow us to gain considerable
information regarding the regulation of sGC activation/stimulation
and will ultimately allow the rational design of ligands interacting in
a largely predictable way with sGC.
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After translation, the sGC-β subunit must undergo heme insertion
and then associate with a partner sGC-α subunit in order to create a
functional heterodimer. We have uncovered important roles for NO
and hsp90 in directing these processes, and are investigating the
molecular and cellular basis for their effects. In cells, our work sug-
gests only the immature and heme-free form of sGC-β is associated
with hsp90, and it does not interact with sGC-α until after the hsp90
helps to drive sGC-β heme insertion in an ATP-dependent process. In
several types of resting cells, and in tissues ex vivo, we find that amixture of immature and mature sGC-β exists, and that NO exposure
can quickly cause the cells to up-regulate heme insertion into the
apo-sGC-β and so drive maturation to the sGC heterodimer. This ef-
fect is seen either with added NO donor or in transwell systems that
contain physically-separated NOS- and sGC-expressing cells. The NO-
driven sGC-β maturation depends on hsp90, because it is blocked by
hsp90 inhibitors or antagonized by an ATP-ase-deficient hsp90 vari-
ant. If the NO exposure (flux) exceeds a certain threshold, the cell’s
sGC-β heme insertion becomes inhibited, coincident with a build up
of SNO on the sGC-β subunit, and its return to association with
hsp90. We are currently determining if and how the SNO events and
heme status of sGC-β are involved in directing its changes in protein
interactions in the cells. In molecular studies with purified sGC-β and
hsp90 proteins, we found their interaction involved the hsp90 M do-
main and the PAS domain of sGC-β. HxD and hydroxyl-radical foot-
printing studies have identified specific regions within these domains
as likely interacting sites. Molecular modelling suggests that hsp90 M
domain interacts with regions of the sGC-β PAS that are also likely in-
volved in sGC heterodimer formation. Point mutation or deletion
within these regions of PAS blocked its interaction with purified
hsp90, and we are now testing the importance of these interactions
for enabling sGC hsp90 interaction, heme insertion, and heterodimer
formation within cells.
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Background:
ATP-binding cassette transporters mediate active efflux of intracellular
cGMP into interstitial space. This extracellular cGMP was shown to
modulate several important physiological processes such as neuronal
survival [1] and visceral hypersensitivity [2]. The identification of the still
elusive molecular target(s) of extracellular cGMP represents an import-
ant step to further enhance our understanding of its role in these pro-
cesses. Here, we have employed a computational approach to identify
the kainate receptor as a potential target for extracellular cGMP.
Materials and Methods:
Ligand similarity and docking analyses were used for target identifi-
cation, and functional assays in primary neurons and transfected cells
to evaluate cGMP as a modulator of kainate receptor function. The
effect of guanine nucleotides on the kainate receptor-mediated ion
flux was studied using patch clamp technique. Cellular permeability
of extracellular cGMP was evaluated using a cGMP-Glo sensor stably
expressed in HEK 293 cells.
Results:
Target identification approach using the structure of cGMP and its 3-
dimensional similarity to ligands with known target was utilized. Ligand-
gated ion channels were identified as primary hits of ligand similarity to
cGMP, with the class of kainate receptors revealing the highest similarity
scores. Next, we used CHO cells transfected with GluK2/5 kainate recep-
tor to evaluate the effect of extracellular cGMP on receptor conductivity
and found GluK2/5-mediated ion current inhibition by cGMP in a
concentration-dependent manner. No effect on GluK2/5-mediated ion
flux was observed when cGMP was tested in agonist or desensitization
mode, with similar results found for GMP and guanosine. Moreover,
when the effect of extracellular cGMP on kainate-receptor activity was
studied in cultured primary human DRG neurons, two types of the
kainate-induced currents were observed: desensitizing and non-
desensitizing currents. Treatment of these neurons with cGMP had no ef-
fect on desensitizing ion current evoked by kainate application. In con-
trast, extracellular cGMP completely inhibited non-desensitizing ion flux,
indicating that human DRG neurons express different sub-sets of hetero-
meric kainate receptors which can differ in their response to kainate and
in their sensitivity to extracellular cGMP.
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 32 of 35Conclusions:
In summary, our computational in silico ligand similarity scoring model
has identified the GluK2/5 kainate receptor as a potential molecular tar-
get for extracellular cGMP, a finding subsequently supported in in vitro
biochemical and functional assays. However, in vivo studies are needed
to further confirm the identity of the GluK2/5 kainate receptor as a tar-
get of extracellular cGMP in relevant animal models.
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Nitric oxide signals through soluble guanylate cyclase (sGC) generating
cyclic guanosine monophosphate (cGMP) to exert essential protective
functions in the cardiovascular system. The possible feedback regulation
of this important pathway in health and disease is incompletely under-
stood. Here we show in pulmonary artery endothelial cells that chronic
exposure to exogenous NO donor drugs or, importantly, also to en-
dogenous NO down-regulates sGC protein and cGMP formation up to
three-fold. Mechanistically, this effect is surprisingly cGMP-independent
and involves oxidative loss of the sGC’s NO-binding heme and formation
of apo-sGC, insensitive to NO. Alternative mechanisms, such as thiol-
dependent modulation appeared not to be involved. In an in vivo dis-
ease model with high levels of NO, acute respiratory distress syndrome, a
similar self-limiting redox shift from NO-sensitive to NO-insensitive apo-
sGC was observed (see Fig. 13). These data suggest a bimodal, non-
equilibrium role for NO signaling by acutely stimulating cGMP formation
and chronically redox inactivating the enzyme towards its apo-form de-
fining a self-limiting chemical feedback. Our findings add to the limita-
tions of still widely used NO donor drugs. The NO-induced apo-state of
sGC can however be functionally recovered by heme mimetic apo-sGC
activator drugs.
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The important role of the cGMP-signalling pathway and its major ef-
fector protein, cGMP-dependent protein kinase I (cGKI), in the cardio-
vascular system is well established. In addition, cGMP-signalling has
long been proposed to play a role in the regulation of stress
BMC Pharmacology and Toxicology 2017, 18(Suppl 1):64 Page 33 of 35responses via the modulation of the hypothalamic-pituitary-adrenal
(HPA) axis. However, the underlying mechanisms including the
cell types and cGMP effectors involved are largely unknown.
To shed light on the role of cGKI in stress responses, we studied
two conditional cGKI mouse models, (1) mice lacking cGKI in the
nervous system, which were generated using a Nestin-Cre line
(cGKI-brain-KO mice), and (2) mice, in which cGKI expression was
abolished from all cells except smooth muscle cells (cGKI-SM-res-
cue mice). We exposed cGKI mutant and control mice to different
stress types and monitored stress hormone levels by immunoas-
says, core body temperature by telemetry and brown adipose tis-
sue (BAT) activity, indirectly, by [18F]FDG PET imaging.
We detected cGKI expression in distinct regions of the hypothal-
amus, pituitary and adrenal gland, as well as in vessels and nerve
bundles of BAT. Interestingly, we found abundant expression of
cGKI in fibroblast-like cells evenly scattered between the steroido-
genic cells of the adrenal cortex and between brown adipocytes
in BAT. Injection of the “immunological stressor” interleukin-1β
elicited increased plasma concentrations of adrenocorticotrophic
hormone (ACTH) and corticosterone (CORT). While cGKI-brain-KO
mice had similar levels of ACTH and CORT as controls, cGKI-SM-
rescue mice showed significantly higher ACTH and, surprisingly,
lower CORT levels than control mice. Compared to controls, CORT
release after direct injection of ACTH was attenuated in cGKI-SM-
rescue mice, suggesting reduced ACTH sensitivity and/or steroido-
genic capacity of their adrenal glands. Cold-stress-induced
thermoregulation was also defective in cGKI mutant mice. cGKI-
brain-KO mice were unable to maintain their core body
temperature when subjected to cold-stress at 4 °C. PET imaging
of cold-stressed cGKI-brain-KO mice revealed reduced [18F]FDG
uptake in BAT compared to controls, indicating a dysfunction of
their BAT.
In sum, this study demonstrates the important roles of cGKI in stress
responses in mice.
Our data suggest that cGKI is mandatory in non-neuronal/Nestin-
negative and neuronal/Nestin-positive cells for a proper stress re-
sponse in the HPA axis and BAT, respectively.
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The authors declare no conflict of interests.Table 4 (Abstract A68). Additive effect of combining miR-425 and miR-
155 on NPPA expression and downstream cGMP levels
1 nM NC
miR
0.5 nM miR-425 + 0.5
nM NC miR
0.5 nM miR-
155
+ 0.5 nM NC
miR
0.5 nM miR-
425
+ 0.5 nM
miR-155
NPPA
expression
1.00±0.02 0.88±0.04 0.87±0.03 0.64±0.04
Nt proANP
levels
1.00±0.20 0.75±0.06 0.89±0.25 0.52±0.08
1 nM NC
miR
1 nM miR-425 1 nM miR-
155
0.5 nM miR-
425
+ 0.5 nM
miR-155
NPPA
expression
1.00±0.03 0.84±0.04 0.83±0.03 0.66±0.02
cGMP levels 1.00±0.08 0.86±0.05 0.90±0.07 0.76±0.05
Values (average±SEM) are shown relative to the negative control (NC)
miRNA valuesA68
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Background:
MicroRNA-425 and miR-155 repress expression of NPPA, the gene
encoding atrial natriuretic peptide (ANP). We investigated
whether treatment with a combination of miR-425 and miR-155resulted in an additive effect on NPPA repression in human
cardiomyocytes.
Materials and Methods:
Human embryonic stem cell derived cardiomyocytes (hESC-CMs)
were transfected with negative control miRNA, miR-425, miR-155, or
a combination. The total amount of transfected miRNA was held con-
stant under all conditions by adding negative control miRNA. Two
days after transfection, NPPA expression was measured via RT-qPCR.
N-terminal (Nt) proANP protein levels in cardiomyocyte media were
assessed using an enzyme-linked immunosorbent assay (ALPCO). A
novel assay was developed to measure the effects of cardiomyocyte
miRNA transfection on downstream cGMP levels. Briefly, COS7 cells
expressing the ANP receptor natriuretic peptide receptor 1 (NPR1)
fused with turboGFP were exposed for two hours to media collected
from hESC-CMs transfected with miRNAs. Next, cGMP levels in these
COS7 cells were measured using an enzyme immunoassay (Cayman
Chemical).
Results:
MicroRNA-425 and miR-155 each decreased NPPA expression in
hESC-CMs over a wide range of concentrations, with a significant
reduction at concentrations as low as 1 nM. The combination of
0.5 nM miR-425 and 0.5 nM miR-155 decreased cardiomyocyte
NPPA expression to a greater extent than either 0.5 nM miR-425
or 0.5 nM miR-155 alone (see Table). In addition, the combin-
ation of miR-425 and miR-155 was more effective at decreasing
secreted Nt proANP protein levels than either miRNA alone (see
Table). Even in comparison with NPPA repression elicited by 1
nM miR-425 or 1 nM miR-155, combining 0.5 nM miR-425 and
0.5 nM miR-155 reduced NPPA expression to a greater extent
(see Table). The additive effect of miR-425 and miR-155 on car-
diomyocyte ANP expression and secretion was associated with a
greater decrease in cyclic 3’,5’-guanosine monophosphate (cGMP)
levels in NPR1-expressing cells. Combining 0.5 nM miR-425 and
0.5 nM miR-155 resulted in a greater reduction in downstream
cGMP levels compared to 1 nM of miR-425 or 1 nM miR-155
(see Table 4).
Conclusions:
These data suggest that greater target repression is obtained by
administering lower doses of two cooperative miRNAs, which
might also produce fewer off-target effects and thus more spe-
cific target regulation.
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Fig. 14 (Abstract A70). Effects of BAY60-2770 on TNF-induced leukocyte
adhesion and recruitment in SCD mice. Effects of BAY60-2770 on TNF-induced
leukocyte adhesion and recruitment in SCD. a Neutrophils from steady-state
SCA patients (N=7) were incubated, or not, with BAY 60-2770 (0.1 – 100 μM;
120 min) before stimulating with TNF (200 ng/ml) and allowed to adhere to
fibronectin-coated plates (30 min, 37oC, 5% CO2). ***, P < 0.001 compared to
basal; #. P<0.05, ##P<0.01, compared to TNF. b-d Intravital microscopy of the
cremaster microcirculation of chimeric SCD mice: (b) Leukocyte adhesion and
(c) leukocyte extravasation at 180 min after TNF-α administration (TNF, 0.5 μg
i.p.) and with co-administration of hydroxyurea (HU, 100 μg/kg) and/or BAY60-
2770 (BAY 60, 10 μg/mouse). N = 32-39 venules of 3-4 mice per group; ***,
P<0.05, compared to CON mice that also received TNF; ###, P<0.05, compared
to TNF. Bar= 20μm. Mann-Whitney or AVOVA/Sidak’s test, as appropriate
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Background:
Gastrointestinal (GI) motility and peristalsis originate from coordinated move-
ments of circular and longitudinal smooth muscle layers. In the enteric nervous
systems, NO is released from nitrergic neurons as a major inhibitory neurotrans-
mitter. GI diseases affecting motility are often associated with impaired nitrergic
signaling. The specific role of nitrergic inhibitory signaling on the circular and
longitudinal muscle layers (CM and LM, respectively) in the small intestine has
not been clearly determined yet. Therefore, in the present study, we investi-
gated the NO-mediated influence on these two muscle layers in murine ileum.
Methods:
As NO-sensitive guanylyl cyclase (NO-GC) is the main receptor for NO in the GI
tract, we first looked for NO-GC expression in murine ileum via immunohisto-
chemistry. For functional analyses, we measured smooth muscle tone in ileal
CM and spontaneous contractions in both ileal muscle layers frommice lacking
NO-GC globally (GCKO) and specifically in smooth muscle cells (SMC-GCKO).
Results:
In contrast to findings from other parts of the GI tract, the immunohistochemical
stainings showed NO-GC expression in platelet-derived growth factor receptor α
(PDGFRα)-positive cells but not in interstitial cells of Cajal (ICC). Organ bath exper-
iments revealed NO-GC in SMC to be involved in the maintenance of tone of
circular smooth muscle: Addition of an NO-GC inhibitor led to an increase and
addition of an NO donor to a decrease in tissue tone. The amplitude of spon-
taneous contractions in CM was increased in the absence of NO-GC. In contrast,
contractile activity in LM was not different between WT and knockout strains.
When activated by NO, NO-GC led to suppression of spontaneous contractions
in WT longitudinal smooth muscle whereas GCKO tissue was unaffected. To our
surprise, NO suppressed spontaneous contractions in longitudinal strips from
SMC-GCKO ileum indicating participation of other cell type(s).
Conclusion:
NO-GC in SMC is involved in the regulation of tone and amplitude of
spontaneous contractions in ileal CM. In LM, NO induces suppression
of spontaneous contractions via NO-GC in a non-SMC type.
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Many of the complications of the hereditary hemoglobinopathy, sickle cell dis-
ease (SCD), result from recurrent vaso-occlusive processes. SCD vaso-occlusion is
triggered by the adhesion of leukocytes (particularly neutrophils) and other
blood cells to activated endothelium, in response to chronic inflammatory and
hypoxic stimuli. The only drug currently approved for SCD therapy is hy-
droxyurea (HU), a drug that may mediate some of its beneficial effects
by releasing nitric oxide (NO). We investigated the effects of the soluble
guanylate cyclase (sGC) activator, BAY 60-2770, on SCD leukocyte adhe-
sion/recruitment, using in vitro static adhesion and intravital tech-
niques. Human neutrophils (2x106cells/ml) were isolated from healthy
controls (CON, N=9) and HbSS sickle cell anemia individuals in steadystate (SCA, N=7). SCA neutrophils demonstrate significantly increased
adhesion to 20 μg/ml fibronectin ligand (30 min), compared to CON
(P<0.05, data not shown), which is further increased by stimulating cells
with 200ng/mL TNF-α (TNF; P<0.001, Fig. 14a), a potent cytokine found
augmented in SCA. Notably, TNF-stimulated adhesion of SCA neutro-
phils was significantly diminished by the pre-incubation of cells with
10-100 μM BAY 60-2770 (120 min; Fig. 14a). Intravital microscopy was
used to look at the effects of BAY 60-2770 on leukocyte recruitment in
the cremaster circulation of chimeric SCD mice (irradiated C57BL6 mice
received transgenic SCD Berkeley mouse marrow). Leukocyte recruit-
ment was induced by the administration of murine TNF-α (TNF; 0.5 μg,
i.p.); in SCD mice, augmented leukocyte adhesion and extravasation
occur, leading to vaso-occlusive-like processes in the microcirculation
following TNF administration (180 min), when compared to chimeric
control mice receiving TNF (CON; C57BL6/C57BL6 transplantation)(Fig.
14b-d). Accordingly, co-administration of HU (100 μg/kg; i.v.) and/or
BAY60-2770 (10 μg/mouse; i.v.), at the time of TNF administration, sig-
nificantly inhibited the adhesion and extravasation of leukocytes in the
microcirculation (P<0.001, comp. to vehicle; N=3-4 for each group, 30-
36 venules analyzed per group), where the BAY60-2770 compound
abolished leukocyte recruitment in a similar manner to that of HU. This
study demonstrates the importance of sGC-cGMP signalling in the
leukocyte recruitment that triggers vaso-occlusive events in SCD and
provides preliminary data to indicate that sGC activators may provide a
potential alternative approach for diminishing leukocyte activation and
occlusive mechanisms and, possibly, even the painful vaso-occlusive
episodes that characterise SCD.
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Introduction:
The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cGMP pathway
is a fundamental signaling pathway in the cardiovascular system with
an established role in controlling vasodilation and local blood flow.
Systemic and pulmonary hypertension, diabetes, and heart failure are
among the diseases associated with endothelial dysfunction and re-
duced NO-cGMP signalling that may treatable by modulators of this
pathway such as IW-1973, a clinical-stage sGC stimulator.
Methods:
W-1973 effects on cGMP production were explored in human recom-
binant sGC enzyme and HEK-293 cell assays. The effect of IW-1973 on
relaxation of human resistance arteries was determined. Hemodynamic
effects of IW-1973 were compared in normotensive Wistar rats and
spontaneously hypertensive rats (SHR). In a Dahl salt-sensitive (DSS) rat
model of hypertension, hemodynamics were monitored over 6 weeks
of treatment with IW-1973, and effects on the cardiac stress marker NT-
proBNP were measured. The pharmacokinetic (PK) profile and tissue
distribution of IW-1973 were determined in rats.
Results:
IW-1973 stimulated cGMP production in sGC enzyme and HEK-
293 cell-based assays (EC50 267 nM and 197 nM, respectively)performed in the presence of the NO donor DETA-NONOate. IW-
1973 demonstrated synergy with NO and required the sGC
holoenzyme. IW-1973 relaxed pre-contracted human resistance
arteries ex vivo (EC50 34.7 nM). IW-1973 demonstrated dose-
dependent mean arterial pressure (MAP) reduction in normoten-
sive rats and SHR. The peak effect on MAP reduction after 3
days of dosing at 10 mg/kg/day was notably greater in SHR
(27.4 ± 0.9 mmHg SEM) relative to normotensive rats (11.3 ± 1
mmHg SEM). In DSS rats, IW-1973 demonstrated sustained MAP
reduction through 6 weeks, and reduced NT-proBNP by 84% at
the 10 mg/kg/day dose. IW-1973 (3 mg/kg/day) at 1 week and
6 weeks reduced MAP to a similar extent as losartan (30 mg/
kg/day) at both timepoints. Oral bioavailability of IW-1973 in
rats was 80-102%, with a Tmax of 8 h, a half-life of 12-22 h, a
large volume of distribution (10-11 L/kg), and hepatic clearance.
IW-1973 was extensively distributed to tissues including heart,
kidney, liver, and lung.
Conclusions:
IW-1973 enhanced NO signalling in vitro and reduced MAP in 2
models of hypertension. Effects of IW-1973 on MAP were
sustained over 6 weeks, with no evidence of tachyphylaxis. IW-
1973 treatment reduced NT-proBNP, a key biomarker of cardiac
stress. "IW-1973 had high oral bioavailability and was exten-
sively distributed to tissues. These results support clinical evalu-
ation of this novel sGC stimulator in cardiovascular diseases,
particularly those associated with impaired NO signalling.Competing interest
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